Optimization of HIV therapy in patients co-infected with tuberculosis: a pharmacogenetic and pharmacokinetic study of efavirenz in Rwandan adult patients undergoing HIV and tuberculosis co-treatment by Bienvenu, Emile
  
 
 
 
 
 
 
Emile Bienvenu 
 
 
 
 
 
 
 
 
 
Department of Pharmacology 
Institute of Neuroscience and Physiology 
Sahlgrenska Academy at University of Gothenburg 
 
 
 
 
 
 
Gothenburg 2013 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Optimization of HIV therapy in patients co-infected with tuberculosis:  
A pharmacogenetic and pharmacokinetic study of efavirenz in Rwandan 
adult patients undergoing HIV and tuberculosis co-treatment 
 
© Emile Bienvenu 2013 
ebienvenu3@gmail.com 
 
ISBN 978-91-628-8834-3  
http://hdl.handle.net/2077/34069 
 
Printed by Ale Tryckteam, Bohus, Gothenburg, Sweden 2013 
 
 
iii 
Emile Bienvenu 
 
Department of Pharmacology, Institute of Neuroscience and Physiology 
Sahlgrenska Academy at University of Gothenburg 
Gothenburg, Sweden 
 
 
Tuberculosis (TB) is the most common opportunistic infection among people 
infected with human immunodeficiency virus (HIV). The co-management of 
HIV/TB co-infection is prone to multiple drug-drug interactions. In addition, 
the recommended HIV drug efavirenz (EFV) has a narrow therapeutic 
window which compromises its clinical safety and exhibits a highly variable 
pharmacokinetics (PK) between subjects due to genetic factors. A lack of 
genomic data on many African populations limits attempts aiming at 
optimizing therapies in general, HIV therapy in particular. This thesis 
specifically aimed to obtain genomic data in an African population and to 
investigate the pharmacokinetic and pharmacogenetic aspects of EFV 
exposure in the presence of TB therapy. 
 
A clinical study was conducted in Rwandan HIV patients co-infected with 
TB. EFV plasma concentrations, CD4 cell counts and HIV-RNA copies 
were monitored. Genotyping for 13 single nucleotide polymorphisms (SNPs) 
with respect to five cytochrome P450 enzymes was conducted. A rapid and 
selective high performance liquid chromatography analytical method was 
developed for the quantification of EFV in plasma containing HIV and TB 
drugs. 
 
Genetic variation was observed in 11 out of the 13 analyzed SNPs with 
minor allele frequencies for 12 SNPs. There was a significant difference 
between CYP1A2 -739T/G and T/T genotypes only in the presence of 
rifampicin-based TB treatment (RBT). In the presence and in the absence of 
RBT, CYP2B6 516T/T genotype was found to be associated with higher 
EFV plasma levels. CYP2A6 1093G>A, CYP2B6 516G>T and CYP2B6 
iv 
983T>C SNPs were found to be independent predictors of EFV plasma 
levels accounting for 27%, 43%, and 29%, respectively, of the total variance 
in EFV plasma levels. There was a high positive predictive value for 
CYP2B6 516T/T and 983T/T genotypes in predicting supra-therapeutic EFV 
plasma levels. RBT was shown to significantly lower EFV plasma levels but 
did not affect HIV-treatment response. There were higher clearance (CL/F) 
values in patients with previous exposure to HIV therapy than in patients 
who were administered RBT prior to HIV therapy. Expectedly, carriers of 
CYP2B6 516G/G and T/T genotypes exhibited higher and lower CL/F, 
respectively, regardless of the previous treatment received by the patients. 
 
In conclusion, CYP enzymes of the accessory metabolic pathways of EFV 
(CYP1A2 and CYP2A6) could explain variability in EFV exposure, in 
addition to CYP2B6 which proved to be the main pharmacogenetic 
determinant of EFV exposure in the patient population studied. As proven by 
the observed high positive predictive value, predictive genotyping in 
CYP2B6 SNPs may be useful in optimizing EFV-based HIV therapy. Not 
only should the patient genotype status with respect to CYP2B6 be taken 
into account, but also each individual patient treatment history, with caution 
to previous exposure to HAART. Even though it is clear from this thesis that 
specific CYP genotypes and co-medications do have a definite effect on 
EFV plasma levels causing its variation, this however does not seem to 
influence the efficacy of the EFV-based regimens in general.  
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Det övergripande målet för den här doktorsavhandlingen var att optimera 
HIV-behandlingen för patienter infekterade med både humant 
immunbristvirus (HIV) och tuberkulos (TB). Bland HIV-positiva personer är 
TB i särklass den vanligaste opportunistiska infektionen och denna grupp är 
också mer känslig mot tuberkelbakterien som orsakar TB. 
Kombinationsterapi, alltså behandling med mer än ett läkemedel, krävs för 
behandling av HIV/TB co-infektioner. Både antiretroviral behandling mot 
HIV och läkemedel mot TB spjälkas i kroppen genom samma metaboliska 
väg, nämligen genom cytokrom P450 (CYP)-systemet. Simultan behandling 
av HIV- och TB-infektion är därför benägen att leda till att de olika drogerna 
påverkar varandra i kroppen (läkemedelsinteraktion) vilket kan påverka 
läkemedlens effektivitet. Efavirenz (EFV) är det läkemedel som 
rekommenderas vid kombinationsterapi vid högintensiv HIV-behandling, 
HAART, hos patienter co-infekterade med TB. EFV har ett snävt 
terapeutiskt fönster som riskerar att påverka läkemedlets säkerhetsprofil hos 
patienten. Utöver detta uppvisar EFV en skiftande farmakokinetik, vilket gör 
att läkemedlet verkar olika mycket i patienter med olika genetisk 
uppsättning. Därtill saknas genomisk litteraturdata från vissa populationer i 
Afrika som också är den kontinent där båda dessa infektioner är vanligast 
förekommande och där den genetiska variabiliteten mellan individer är 
mycket stor. 
 
Den här avhandlingen fokuserar bland annat på att kartlägga den genetiska 
uppsättningen hos personer i en population i Rwanda . De gener som särskilt 
studerats är involverade i spjälkningen av vanligt förekommande läkemedel 
som används vid behandling av olika typer av infektioner, inklusive 
antiretrovirala läkemedel. Dessutom undersöktes EFVs farmakokinetik och 
farmakogenetik då det användes tillsammans med TB-läkemedel. Effekterna 
av TB-behandling och långtidsterapi med HIV-läkemedel med avseende på 
farmakokinetiken hos EFV studerades också.    
 
En klinisk studie utfördes i Rwanda där testpersonerna var co-infekterade 
med HIV och TB. EFV plasma-koncentrationer, antalet CD4-celler och 
antalet HIV-RNA kopior beräknades vid givna tidpunkter och fem CYP-
enzymer genotypades.  Samtidigt utvecklades en snabb, högpresterande 
vätskekromatografimetod för kvantifiering av EFV i plasma innehållande 
HIV- och TB-läkemedel.  
 
vi 
Resultaten från genotypningen visade att den genetiska variationen mellan 
testpersonerna inom Rwanda-gruppen var mycket stor men resultaten skilde 
sig även från populationer från andra länder, så som Kamerun och Sydafrika. 
Den huvudsakliga genetiska faktorn som kunde kopplas direkt till skillnader 
i EFV-nivåerna i plasma var CYP2B6-genen som uttrycker enzymet 
cytochrome P450 2B6 involverat i spjälkningen av EFV-läkemedlet. 
Genetiska skillnader i CYP2B6-uttrycket mellan olika individer kunde 
förklara 72% av de totala variationerna i EFV-nivåerna. Ett positivt 
prediktivt värde upptäcktes för CYP2B6-varianterna och detta indikerade att 
det skulle kunna vara viktigt att använda genotypning som ett verktyg för att 
identifiera de patienter som finns i riskzonen för förhöjda EFV-nivåer. För 
höga nivåer av EFV i plasma kan leda till ökad neurotoxicitet och 
läkemedelsdosen bör i sådana fall justeras. Hos patienter som behandlas för 
kombinationen HIV/TB-infektion sker läkemedelsinteraktioner i kroppen 
mellan läkemedlen där särskilt TB-farmaka tenderar att kraftigt minska 
nivåerna av EFV i plasma och långtidsterapi med antivirala medel ökar 
elimineringen av EFV. Resultaten visar att TB-farmakas påverkan på EFV 
plasmanivåerna bör tas på allvar men justering av läkemedelsdosen bör 
övervägas endast då utfallet av behandlingen påverkas, särskilt i de fall då 
patienten genomgår HIV-terapi. 
 
Sammanfattningsvis föreslår vi att den genetiska uppsättningen med 
avseende på CYP2B6 bör analyseras samtidigt som varje patients tidigare 
behandlingar bör beaktas, i synnerhet eventuell tidigare HIV-terapi.  
 
Trots att våra resultat och tidigare publicerade studier visar att den genetiska 
bakgrunden ihop med behandling med en kombination av flera läkemedel 
påverkar EFV plasmanivåerna kan de inte kopplas direkt till en generellt 
minskad effektivitet av EFV-baserad terapi.  
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Pharmacogenetics The study of inter-individual genetic variation 
that gives rise to differing response (both 
safety and efficacy) to drugs 1. 
 
Pharmacogenomics The identification of the genes that influence 
drug response 1. 
 
Pharmacokinetics The study of how a drug is absorbed, 
distributed, metabolized, and excreted 2. 
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With the overall aim of contributing to the optimization of HIV therapy in the 
context of HIV and TB co-treatment, this thesis focuses mainly on the 
pharmacogenetics of EFV exposure in the presence of TB therapy and the 
effects of TB and long term HIV treatments on the pharmacokinetics (PK) of 
EFV. 
 
Tuberculosis (TB) is the most common opportunistic infection among people 
infected with human immunodeficiency virus (HIV) 3. HIV infected 
patients are more sensitive to develop TB than those who are HIV-negative 
4. The standard regimen for the treatment of TB is a combination of two to 
four drugs 5. The recommended first line highly active antiretroviral 
therapy (HAART) for the management of HIV involves a combination of 
three drugs consisting of two nucleoside reverse transcriptase inhibitors 
(NRTIs) with a non-nucleoside reverse transcriptase inhibitor (NNRTI) 6.  
 
The HIV drug of focus of this thesis is efavirenz (EFV). EFV is the NNRTI 
recommended as part of HAART either in patients infected with HIV alone 
or co-infected with TB, because of good tolerance with superior clinical 
outcomes compared to other NNRTIs 6-10. Moreover, EFV itself has a PK 
profile that deserves a particular attention. EFV is highly protein bound 
(>99%), has a long steady-state half life (40-55 hours) and a narrow 
therapeutic window, which ranges between 1 and 4 g/ml. Plasma levels of 
EFV below 1 g/ml and above 4 g/ml have been associated with increased 
risks of therapeutic failure and central nervous system (CNS) side effects and 
toxicity, respectively 11. In addition, EFV has been shown to induce its 
own metabolism and hence accelerating its own elimination 12-14. 
 
The relationship between a drug’s pharmacokinetic and pharmacodynamic 
properties governs the time course of drug action. Thus, factors affecting the 
drug’s PK could influence the expected treatment outcome 2. High inter-
individual variability in the PK of EFV following the administration of the 
fixed once daily adult dose of 600 mg has been reported 11, 15-19. This is 
most likely caused by a combination of multiple factors including biologic  
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and genetic factors, as well as drug-drug interactions 20. These are major 
concerns to address when attempts aiming at optimizing the therapy of HIV 
are made. Particularly, in the context of HIV and TB co-treatment drug-drug 
interactions represent an important challenge due to the fact that managing 
HIV and TB co-infections requires multidrug therapy. 
 
Genetic polymorphism is the most important factor affecting the PK of 
antiretroviral (ARV) drugs, including EFV 20. A lack of genomic data on 
many African populations limits attempts aiming at optimizing therapies in 
general, HIV therapy in particular. Currently, Africa is under-represented in 
genetic screening 21, whereas it is the most affected continent with respect 
to major infectious diseases 22-24 and presents with the most genetic 
diversity 25-27. A pharmacogenomic study was performed in a Rwandan 
population with respect to genes coding for proteins involved in the 
metabolism of commonly used anti-infectious drugs, including antiretrovirals 
(Paper II). 
 
EFV is mainly metabolized in humans by hydroxylation catalyzed by 
cytochrome P450 (CYP) 2B6, and to a lesser degree by CYP1A2, CYP2A6, 
CYP3A4 and CYP3A5 31-38. Thus, factors affecting the metabolism of 
EFV could influence EFV exposure and the treatment response. Therefore, 
this variability in EFV PK is thought to be caused by inter-individual 
differences in CYP activity and expression 18, 20-29, 32. The effects of ten 
SNPs in CYP genes on EFV plasma levels and on treatment response in the 
absence and presence of TB therapy was investigated. Moreover, whether 
there are additional SNPs that could be used to enhance the prediction of 
EFV exposure (independent predictors) was analyzed (Paper III). 
 
Therapeutic management of HIV/TB co-infection may result in complex PK 
drug-drug interactions taking place collectively between HAART 
components and TB drugs, impacting on blood levels of both HIV and TB 
drugs. Indeed, both ARV and TB drugs share metabolic pathways through 
the CYP system 33, 34, some being inhibitors or inducers of CYP enzymes 
35. As a consequence, multiple interactions take place during the co-
management of HIV/TB co-infection, where EFV-based HAART is 
concomitantly administered with rifampicin-based TB treatment (RBT). The 
induction effect of rifampicin on EFV metabolizing enzymes (CYP2B6 and 
CYP3A4) has been demonstrated 36-39. Particularly, CYP2B6 has been 
studied in different populations 39-41. Moreover, EFV has been shown to 
induce CYP2B6 and CYP3A4, accelerating its own metabolism 12-14. 
These issues were addressed in this thesis, by investigating the effects of  
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RBT on EFV exposure and on the clinical response (Paper III) and by 
estimating the clearance (CL/F) value taking into account not only CYP2B6 
genetic polymorphism, but also enzyme induction arising from EFV-based 
HAART and from RBT (Paper IV).  
 
One of the important aspects in therapy optimization is monitoring patients 
during treatment, especially when the drug has a narrow therapeutic window 
and an apparent correlation between high plasma levels and a high rate of 
side effects and toxicity. In the context of HIV management, monitoring 
patients’ plasma levels (known as therapeutic drug monitoring or TDM) has 
been recommended for EFV 42 and genotyping has proven to be useful in 
the prediction of the pre-disposition to low or high EFV levels in clinical 
studies 43, 44. However, the main challenges in implementing TDM are the 
availability of validated and simple quantification assays with high 
selectivity, small sample volume requirements, and rapid turnaround time for 
the measurements. In addition, the assay needs to be cost-effective in order to 
guarantee its applicability and sustainable use, especially in resource limited 
settings 35, 45. In this perspective, a rapid and selective analytical method 
for the quantification of EFV in human plasma containing first line 
medications used for the management of both HIV/AIDS and TB was 
developed and validated as to contribute to the applicability of TDM in 
resource limited settings (Paper I). Furthermore, regarding monitoring 
patients through genotyping, there are still some concerns, about the clinical 
utility of routinely screening for genetic markers and the applicability to the 
broader population of data from stratified population 45, 46. In Paper III, 
the validity of genotyping in each of CYP2B6 SNPs in predicting EFV 
plasma levels was evaluated. 
 
This thesis is a presentation of studies that were conducted to shed more light 
on the optimization of HIV therapy. The overall aim of this thesis is 
described in Chapter 2, along with specific aims which were addressed 
through papers mentioned in above paragraphs. Multiple aims were 
addressed in some of the papers, whereas single aims were studied in others. 
Patients and methods are detailed in Chapter 3, while summary results and 
discussion are presented in Chapter 4. The main conclusions from this work 
are outlined in Chapter 5.  
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World Health Organization (WHO) recently reported that in 2012, an 
estimated 35.3 million people were living with HIV. HIV refers to human 
immunodeficiency virus. There are two types of HIV: HIV-1 and HIV-2. 
HIV-1 is responsible for the vast majority of HIV infections globally. These 
two viruses have been identified as the primary cause of acquired 
immunodeficiency syndrome (AIDS). In this thesis, HIV refers to both HIV-
1 and HIV-2 unless otherwise indicated 47. 
 
 
In the beginning, the newly HIV-infected individual exhibits no symptoms. 
Slight changes in the immune system follow and take place progressively; 
individuals can within two to four weeks after infection with HIV experience 
an acute retroviral syndrome or primary HIV infection. It is the body’s 
natural response to the HIV infection taking up to 3 months for it to appear in 
some people. Although individuals may look healthy during primary 
infection, the virus is actively replicating. As a result, the immune system 
may get slowly damaged and individuals may develop symptoms of the late 
phase of HIV disease (AIDS) where individuals are susceptible to other 
opportunistic infections, such as infections with Mycobacterium tuberculosis, 
Pneumocystis carinii, toxoplasmosis and candidiasis, etc. Infected individuals 
are diagnosed as having AIDS status when their plasma HIV load is high and 
the CD4 cell counts falls below 200 cells/ mm
3
(normal CD4 counts are 
between 500 and 1.600 cells/mm
3
) 48, 49. 
 
The primary and essential receptor for HIV is the CD4 lymphocyte cell 
which is involved in the induction of most immunologic functions. It has 
been suggested that the CD4 cell is the high-affinity receptor for the virus. 
The CD4 cell needs to use the chemokine receptor as essential co-receptor for 
HIV entry into other cell types such as monocytes and dendritic cells 48, 
50. After HIV binds to the CD4 cell, the virus is internalized and uncoated 
followed by the transcription of the genomic ribonucleic acid (RNA) to 
deoxyribonucleic acid (DNA)  by the enzyme reverse transcriptase. The 
proviral DNA is integrated into the host chromosomal DNA (Figure 1). At 
this stage, the infection is in a latent phase until the infected cells are 
activated. Once the cell is activated, the proviral DNA transcribes viral 
genomic RNA and messenger RNA. Protein synthesis, processing, and virus  
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assembly occur with budding of the mature virion from the cell surface. 
When active replication of virus occurs, the host T-cell is usually killed. This 
results in progressive depletion of CD4 cells. At this stage, profound immune 
suppression occurs, resulting from removal of CD4 cells from the immune 
system rending it progressively weaker and unable to control subsequent 
infections 49.  
 
 
 
Figure 1. HIV life cycle and the sites of action for available antiretroviral drugs. 
NRTIs: nucleoside reverse transcriptase inhibitors;  
          NNRTIs: non-nucleoside reverse transcriptase inhibitors;  
          PIs: protease inhibitors; RT: reverse transcriptase;  
          CCR5: C-C chemokine receptor type 5. From Apostolova et al. (2011)51. 
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1.2.2.1 Treatment goals 
The primary goals for initiating antiretroviral therapy are to reduce HIV-
associated morbidity and prolong the duration and quality of survival, restore 
and preserve immunologic function, maximally and durably suppress plasma 
HIV viral load, and prevent HIV transmission 42.  
 
1.2.2.2 Current approach to treatment 
The combined pharmacological approach to the treatment of HIV infection, 
known as highly active antiretroviral therapy (HAART) is a combination of 
antiretroviral drugs grouped in five classes according to the mechanism of 
which they interrupt the HIV life cycle 51 (Figure 1). The major classes are 
nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs). There are 
three new antiretroviral classes, namely integrase inhibitors, chemokine 
receptor type 5 (CCR5) inhibitors and fusion inhibitors 51-58 (Figure 1). 
 
1.2.2.3 Recommend first-line antiretroviral therapy 
Current WHO guidelines for the management of HIV infection recommend 
first-line treatment composed by two NRTIs combined with one NNRTI. The 
recommended HAART consists of an NNRTI (either nevirapine -NVP- or 
efavirenz -EFV-) plus two NRTIs, one of which being lamivudine (3TC) or 
emtricitabine (FTC) and the other zidovudine (AZT) or tenofovir (TDF). The 
less toxic and more convenient fixed-dose combination recommended for 
first-line HAART is once-daily regimen comprising TDF+3TC (or 
FTC)+EFV). This combination therapy is the preferred option to initiate 
HAART in adults, adolescents and children older than three years. For 
children younger than three years, a PI-based regimen is the preferred 
approach. If the above recommended combination is contraindicated or not 
available, one of the following options is recommended: AZT+3TC+EFV or 
AZT+3TC+NVP or TDF+3TC (or FTC)+NVP. Of note is that EFV is 
preferred to NVP because people receiving NVP are twice as likely as those 
receiving EFV to discontinue treatment because of adverse events. For 
pregnant and breastfeeding women, a once-daily fixed-dose combination of 
TDF+3TC (or FTC)+EFV is recommended as first-line HAART as well. 
Infants of mothers who are receiving HAART and are breastfeeding should 
receive six weeks of infant prophylaxis with daily NVP 47.  
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TB is an infection caused by a bacterium called Mycobacterium tuberculosis 
that affects the lungs. It is transmitted after expectoration when an infected 
individual coughs, sneezes or talks, expelling the Mycobacterium 
tuberculosis, usually contained in droplet nuclei. Mycobacterium tuberculosis 
sometimes causes illness soon after the initial exposure (active TB), but an 
immune-competent system can prevent Mycobacterium tuberculosis from 
causing illness (latent TB). It may happen however, that Mycobacterium 
tuberculosis causes illness years later (reactivation TB). The droplets, when 
expelled, can remain airborne for minutes to hours. Once the infectious 
droplet nuclei are inhaled, Mycobacterium tuberculosis is taken up by 
alveolar macrophages, initiating a cascade of events that result in either a 
successful containment of the infection or progression to active disease 59. 
The CD4 positive T lymphocytes cells are involved in these event cascades. 
After being ingested by alveolar macrophages, Mycobacterium tuberculosis 
replicates and spreads via the lymphatic system to the hilar lymph nodes. The 
infected macrophage releases interleukins 12 and 18, which stimulate CD4 T 
lymphocytes to release interferon γ. This interferon γ then stimulates the 
phagocytosis of Mycobacterium tuberculosis in the macrophage. Interferon γ 
also stimulates the macrophage to release tumor necrosis factor α, which is 
important in the formation of granuloma and control of the extent of 
infection. When the host immune response fails to contain the replication of 
Mycobacterium tuberculosis associated with initial infection, active disease 
occurs.  In immune-competent individuals, granulomas are highly effective in 
containing, but not eliminating, the infection 60, 61.  
 
1.3.2.1 Aims of treatment 
The aims of treatment of TB are to cure the patient and restore quality of life 
and productivity, to prevent death from active TB or its late effects, to 
prevent relapse of TB, to reduce transmission of TB to others, and to prevent 
the development and transmission of drug resistance 5. 
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1.3.2.2 Standard regimens for the treatment of TB 
The TB drugs recommended in the WHO guidelines are ethambutol (E), 
isoniazid (H), rifampicin (R) and pyrazinamide (Z). Streptomycin is indicated 
when one of these drugs is contraindicated. New patients with pulmonary TB 
may receive a daily intensive phase treatment with RHZE for 2 months, fol-
lowed by three times weekly continuation phase with RH, provided that each 
dose is directly observed ([2(RHZE)7/4(HR)3]; numbers before the letters 
indicate the months of duration of the treatment for the intensive treatment 
phase; subscripts indicate how often the treatment is taken each week). Three 
times weekly dosing throughout therapy (2(RHZE)3/4(HR)3) may be used 
when necessary as another alternative to above recommendation, provided 
that the patient is not living with HIV 5. Otherwise the optimal dosing 
frequency for new patients with pulmonary TB is daily throughout the course 
of therapy wherever feasible 5.  
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Infection with HIV is the most potent risk factor for TB, with an increased 
risk of more than 20-times compared to those not infected with HIV 59. 
 
 
The 2013 global TB report indicates that the prevalence of TB in the world 
was estimated to 8.6 million people in 2012 and the total number of those co-
infected with HIV was 1.1 million (13%). Of these, 75% were in countries of 
the African Region. Regarding the number of deaths, of the 8.6 million cases 
of TB 1.3 million died and 320 000 (representing 25%) were co-infected with 
HIV. The same report further indicates that 26% of TB patients were co-
infected with HIV in the year 2012 in Rwanda 3.  
 
 
Without treatment, HIV and TB interact, accelerating the deterioration of 
immunological functions and shortening lifespan. It has been reported that 
TB infection exacerbates HIV infection. Epidemiological data showed that 
the incidence and mortality rates for new AIDS-defining opportunistic 
infections were higher if individuals with HIV were co-infected with TB 62, 
63. On the other hand, the progression from latent to active TB was reported 
to be increased in HIV/TB co-infected patients, compared to TB mono-
infected patients. The depletion of CD4 cells by HIV infection is believed to 
be an important contributor to the increased risk of reactivation of latent TB 
62, 64. 
 
 
WHO guidelines recommend that HIV testing should be initiated for all 
patients with known or suspected active TB and that TB patients living with 
HIV receive the same duration of TB treatment as HIV-negative TB patients. 
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1.4.3.1 HIV/TB patients not yet receiving antiretroviral therapy 
WHO recommended that TB treatment should be initiated first in all HIV/TB 
patients. HAART should follow as soon as possible, and within the first eight 
weeks regardless of CD4 cell counts 3, 47. New HIV/TB patients should be 
treated with the TB regimens given in section 1.3.2.2, and with HAART 
consisting regimens described in section 1.2.2.3. EFV-based HAART 
regimens are preferred to NVP ones because of less interactions between 
EFV and TB drugs 5, 47.  
 
1.4.3.2 Patients diagnosed with tuberculosis while on antiretroviral therapy 
When TB is diagnosed in patients already receiving antiretroviral therapy, TB 
treatment should be started immediately. Before initiation of TB treatment, it 
must be considered whether HAART needs to be modified because of drug-
drug interactions or to reduce possible overlapping toxicities. 
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EFV is the recommended NNRTI, dosed once daily, for the treatment of HIV 
infection alone or of HIV/TB co-infection 47, 65. EFV has a narrow 
therapeutic window ranging between 1 and 4g/ml (3.2 and 12.6 μM, 
respectively) 11, 66, 67. 
 
 
Pharmacokinetics is the study of how the body affects a drug, and is 
described by how a drug is absorbed, distributed, metabolized, and excreted 
2. 
 
1.5.1.1 Pharmacokinetic properties of efavirenz 
Following EFV 600 mg once-daily administration, peak plasma 
concentrations (Cmax) at steady-state were 12.9 ± 3.7 μM (mean ± SD), trough 
plasma concentrations (Cmin) were 5.6 ± 3.2 μM, and areas under the plasma 
drug concentration-time curve (AUC) were 184 ± 73 μM*h. Cmax was reached 
3 - 5 hours after dose. Steady-state plasma concentrations were reached in 6 - 
7 days. The oral bioavailability of EFV is 40-45% without food 65, 68. Fat-
containing meals increase absorption significantly 65, 68, 69. EFV is highly 
bound (approximately 99.5-99.75%) to human plasma proteins, 
predominantly albumin. EFV is principally metabolized by the CYP system 
to essentially inactive hydroxylated metabolites followed by glucuronidation. 
Approximately 14-34% of the EFV dose is excreted renally primarily as 
metabolites and 16-61% of the dose is excreted in the feces as parent drug. 
EFV has a relatively long terminal half-life of 52-76 hours after single doses 
decreasing to 40-55 hours after multiple doses 65, 68. EFV has been shown 
to induce CYP enzymes among which CYP2B6 14, 68, resulting in the 
induction of also its own metabolism 12-14. A population PK analysis 
performed to assess the PK profile of EFV in HIV patients reported an 
absorption rate constant (Ka) of 0.3 h
-1
, a CL/F of 9.4 L/h and a volume of 
distribution (V/F) of 252 L 16. 
 
1.5.1.2 Influence of biological factors on EFV pharmacokinetics 
While genetic factors are considered as the most important determinant of the 
PK of EFV 20, there is no conclusive evidence to suggest that biological 
factors such as gender and body weight significantly influence EFV plasma 
levels. In some studies, higher EFV plasma levels were found in women  
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compared to in men 70, but in other studies no sex-related differences in 
EFV levels have been found 16, 71-73. On the other hand, some authors 
found the body weight to be associated with clearance or EFV plasma levels 
15, 73, while others did not find such association 70, 74, 75. However, 
ethnicity has been consistently associated with EFV plasma levels such that 
Blacks or Asians tend to have higher EFV plasma levels than Whites 16, 70, 
76, 72-75, which probably reflects host genetics. In this work, the 
relationship between demographic variables and EFV plasma levels was 
investigated in Paper III. 
 
 
EFV-related neurotoxicity is the most important among EFV adverse 
reactions 68, 81, 82. Most common disorders in the CNS following EFV 
use are confusion, dizziness, insomnia, somnolence, impaired concentration 
and abnormal dreaming, anxiety and depression 68, 81, 82. Other common 
EFV adverse reactions are metabolic and nutrition disorders (increases in 
fasting triglycerides, total and lipoprotein cholesterol), hepatobiliary 
disorders (elevation of liver enzymes), skin and subcutaneous rashes 68.   
 
 
Pharmacogenetics refers to the study of inter-individual genetic variation that 
gives rise to differing response (both safety and efficacy) to drugs 1. 
Indeed, host genetic polymorphisms in drug metabolizing enzymes influence 
drug clearance and response 83.  
 
1.5.3.1 Role of CYP enzymes in the metabolism of efavirenz 
The suggested metabolic pathways of EFV are shown in figure 2. The drug is 
mainly metabolised by the CYP system through hydroxylation into two 
primary metabolites, namely 8-hydroxy-EFV (8-OH-EFV) and 7-hydroxy-
EFV (7-OH-EFV) 31, 84. The 8-OH-EFV metabolite is the main one 29-
31, 84 accounting for 77% of the overall EFV metabolism 30. It is 
principally formed by CYP2B6 30, 31, 84, with small contribution of 
CYP1A2, CYP3A5, and CYP3A4 31. In vitro, CYP2A6 seems to 
contribute to the formation of 8-OH-EFV 30. 7-OH-EFV is the second most 
important metabolite 29-31, 84 accounting for 23% and mainly formed by 
CYP2A6 15 and to some extent by CYP2B6 29. In addition to the primary 
hydroxylation, about 17% of 8-OH-EFV formed was found in vitro to 
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subsequently oxidize mainly by CYP2B6 31 and to a lesser extent by 
CYP2C9 31, 41 to the secondary metabolite 8,14-dihydroxy-EFV.  
 
In addition, EFV also undergoes direct conjugation by uridine diphosphate 
glucuronyltransferase (UGT) to form N-glucuronide 30, 15, 48. Both 7-OH-
EFV and 8-OH-EFV subsequently undergo urinary and biliary excretion after 
glucuronidation 28, 15. Alternate pathways such as 7–hydroxylation by 
CYP2A6 and glucuronidation by UGT were reported to play an important 
role in individuals with reduced CYP2B6 activity 29.  
 
 
 
Figure 2. Suggested metabolic pathways for efavirenz and its catalytic 
hepatic enzymes.  
 
1.5.3.2 Influence of genetic variants on efavirenz pharmacokinetics 
Inter-individual variability in EFV plasma levels following the administration 
of the fixed adult dose of 600 mg of EFV was found to be up to 120% 11, 
whereas the reported coefficient of variation in oral clearance of EFV ranged 
from 40 to 55% 15-17. Inter-individual variability in the PK of EFV was 
thought to be caused by a combination of multiple factors including biologic, 
exogenous and genetic factors; the latter being considered as the most 
important factor 20.  
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The gene that encodes for CYP2B6, the main metabolizing enzyme of EFV, 
is highly polymorphic. CYP2B6 is thus subject to large inter-individual 
variability in expression and activity 18, 32, 84, 85, 76. CYP2B6 516G>T 
SNP is the most important; CYP2B6 516T/T genotype has been consistently 
associated with reduced enzyme activity and higher EFV exposure in 
different patient populations when compared with G/T or G/G genotypes 43, 
70, 76, 86-89. The frequency of the 516T/T variant was higher in African-
Americans (20%) and European-Americans (3%) 90. CYP2B6 983T>C 
SNP shares similar characteristics with CYP2B6 516G>T 41, 74, 76, 91, 
appears to be exclusively found in populations of African descent and was 
also found to be associated with lower enzyme activity and higher EFV levels 
18, 32, 85. CYP2B6 785A>G SNP was also reported to be associated with 
reduced enzyme activity and elevated EFV levels 41, 46. Other CYP2B6 
polymorphisms that have been identified have minimal impact on EFV 
metabolism 92. Recently, CYP2A6 genetic polymorphisms 15, 29, 74, 
CYP3A4*1B and CYP3A4_rs4646437 15 have also been found to 
influence EFV plasma concentrations or clearance. In this work, the 
genomics of an African population in five genes coding for proteins involved 
in the metabolism of commonly used anti-infective drugs, including 
antiretrovirals was investigated in Paper II and the role of ten SNPs of these 
genes on EFV plasma levels was studied in Paper III. 
 
1.5.3.3 Pharmacogenetics of efavirenz-related neurotoxicity 
EFV plasma levels above 4 g/ml have been associated with increased risks 
of CNS toxicity 11, 41, 77-80. 516G>T SNP of CYP2B6 is associated with 
increased plasma EFV exposure as described in 1.5.3.2. This is suggestive of 
association between CYP2B6 516T/T genotype and CNS toxicity. This has 
been demonstrated in different studies where individuals harboring CYP2B6 
516T/T genotype were found to present with a higher incidence of CNS 
toxicity during the first week of therapy 76, 88, 89. Since CYP2B6 
785A>G and 983T>C SNPs are associated with increased EFV levels 9, 16, 
49, 41, 46, individuals with these SNPs could develop EFV-related CNS 
toxicity 41, 46, 76, 88, 89. 
 
 
 
 
 
 
 
Optimization of HIV therapy in patients co-infected with tuberculosis 
 
15 
 
Pharmacokinetic drug-drug interactions are consequences of the effect of one 
drug that alters the absorption, distribution, metabolism or excretion of 
another drug. This could lead to altered levels of exposure to the latter and 
possibly altered drug response 33, 36, 37. Interactions at the level of hepatic 
excretion were reported to be the most important when TB and ARV drugs 
are co-administered 33. 
 
 
Drug-drug interactions between ARV and TB drugs are one of the major 
challenges that face the therapeutic management of HIV/TB co-infection 35, 
93. Many ARV and TB drugs share the same metabolic pathways through 
the CYP system. Many of them induce or inhibit the CYP system, and may 
affect the clearance of co-administered drugs 33, 34. For example, EFV has 
been shown to induce hepatic CYP2B6 and CYP3A4 14, 94, 95, hence to 
accelerate not only its own metabolism 33, 12-14, but also that of co-
administered TB drugs that share these metabolic pathways 33, 34. On the 
other hand, some recommended TB drugs were reported to affect ARV 
metabolizing enzymes 36, 37, 41, 35, 96. Rifampicin was reported to be a 
potent inducer of CYP enzymes, such as CYP2B6, CYP1A2 and CYP3A4 
enzymes 19, 36, 37, 41 and UGT-1A1 enzyme 33. Isoniazid and 
pyrazinamide were reported to exhibit the inhibitory effects in vitro on EFV 
hydroxylation in CYP1A2, CYP2A6, CYP2B6 and CYP3A4 enzymes 97, 
98. In addition isoniazid has been shown to induce CYP3A enzyme 37. 
Thus, the therapeutic management of HIV/TB co-infection may result in 
complex PK drug-drug interactions taking place collectively between 
HAART components and TB drugs, impacting on blood levels of both HIV 
and TB drugs. The clinical relevance of their consequences has been reported 
controversially and still needs validation 99-102.  
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Rifampicin induces the function and activity of CYP2B6, the main 
metabolizing enzyme for EFV 19, 41. In primary human hepatocytes, the 
increase in CYP2B6 activity due to rifampicin varies widely from 2.5- to 13-
fold 103-105. In vivo, co-administration of EFV with RBT was reported to 
lead to accelerated EFV clearance with reduction in EFV exposure differing 
from one cohort to another 19, 83, 99-102, 106. Reduction in EFV exposure 
was either modest 19, 83 or significant 99-102, 106 during co-treatment of 
HIV and TB. The variability in EFV plasma levels was found to be greater in 
the presence of RBT than without RBT, which is probably a manifestation of 
inherent differences in the inducibility of CYP2B6 variants in patients 99, 
108. Reports on whether EFV doses need to be modified to be compatible 
with RBT are still conflicting (see section 1.6.3). Nevertheless, TDM is 
thought to be a useful tool to monitor EFV levels and should prompt 
assessment of drug adherence after determining the drugs and doses to use 
42. In this work, the influence of RBT on EFV plasma levels in the 
population studied was investigated in Paper III. 
 
Paradoxically, elevated EFV plasma levels in the presence of RBT were 
recently reported by Gengiah et al. (2012) 109 and Luetkemeyer et al. 
(2013) 110, both pointing out that the underlying mechanism for this 
observation remains unclear. 
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Two reasons may dictate dose adjustment for EFV during co-management of 
HIV and TB. First, EFV is associated with significant inter-individual 
variability in plasma levels 11, 16, 66 as described in section 1.5.3.2. 
Secondly, concurrent HIV and TB therapy is necessary for the management 
of both infections, but at the same time it is challenged by managing the 
consequences of interactions between EFV and rifampicin that may decrease 
EFV exposure 11, 16, 66. The concern is that the fixed daily dose of EFV 
600 mg for adults may consequently result in supra- or sub-therapeutic EFV 
levels 18, 32, 85, 76, leading to CNS toxicity and treatment failure followed 
by development of drug resistance, respectively 11, 16, 66, 67. Therefore, 
the goal of adjusting the dose for EFV when co-administered with RBT is to 
avoid EFV plasma levels outside the therapeutic window, thus preventing 
related consequences. Tailoring EFV dose should be done at individual level 
and take into account the individual genotype. For example, carriers of 
CYP2B6 516 T/T genotype (slow metabolizers) are at risk of high EFV 
levels even in the presence of RBT 75, 111. Thus, increase in EFV dose 
during RBT may not be necessary in slow metabolizers. 
 
Several reports on increase in EFV clearance followed by reduction in its 
plasma exposure after concurrent administration of RBT and EFV has led 
some experts to recommend an increased EFV dose to 800 mg/day when co-
administered with RBT 6, 35, 112. Comparative studies were conducted 
and no clinical advantages of the increased dose have been found 100, 113. 
A recent clinical study in South Africans comparing 600 mg to 800 mg of 
EFV during TB treatment concluded that dose escalation of EFV 600 mg to 
800 mg is not required during concomitant TB therapy in South Africans, 
based on the fact that the proportion of virologically suppressed individuals 
at 48 weeks was similar in both groups 113. These findings were consistent 
with those of another previous randomized study on EFV 600 mg vs 800 mg 
daily conducted in Thai patients where no difference in virological outcome 
between the two groups was observed 100. In addition, another study that 
recruited predominantly native Africans reported that the increased dose of 
800 mg was associated with a high frequency of CNS and hepatic toxicities 
associated with high EFV plasma levels 114. In conclusion, there is no 
sufficient evidence to support an increase in EFV dose to 800 mg/day in 
HIV/TB co-infected patients; this was also concluded in a review of available 
literature conducted in 2008 by FDA 115. 
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1.8.1.1 Definitions 
The term “allele” indicates a different form of a gene at a particular locus on 
a chromosome. Genotype refers to the pair of alleles present at a single locus 
of an individual (genetic make-up). Thus, genotyping consists of determining 
the genetic constitution (the genotype) of an individual by examining the 
deoxyribonucleic acid (DNA) sequence. The genotype defines a given 
characteristic, condition or disease. Hence, genotyping helps in finding the 
origin and the pre-disposition of a disease, a characteristic or a condition. 
DNA sequence variations occurs when a single nucleotide in the genome 
sequence is altered and this refers to single nucleotide polymorphisms (SNP). 
Variations in the DNA sequences (SNPs) influence how humans develop 
diseases, respond to drugs, etc. Thus, knowledge of this variation in SNPs 
helps in understanding and treating human diseases 116.  
 
A predictive genetic test is performed with the purpose to investigate whether 
an individual presents a pre-disposition to a disease or to developing drug 
toxicity 117. 
 
1.8.1.2 Predictive genotyping for patients treated with efavirenz 
In section 1.5.3.3, the association between CYP2B6 SNPs and increased EFV 
plasma levels and high incidence of CNS toxicity was discussed. Mallal et al. 
2007 46 indicated that genotyping could be a useful patient management 
tool for identifying individuals at risk of genetically influenced drug toxicity. 
Drugs of concern are those exhibiting a narrow therapeutic window and those 
metabolized by the polymorphic enzymes 46. EFV itself exhibits a narrow 
therapeutic window that may put patients at risk of CNS toxicity 11 and is 
metabolized by a polymorphic enzyme (CYP2B6) potential to alter plasma 
levels 43, 70, 76, 86-89. Accordingly, genotyping for CYP2B6 variants in 
patients receiving EFV has been suggested as a clinical tool that may help 
identifying patients at greatest risk of developing CNS toxicity and who may 
need adjusted EFV dose 43, 44. FDA has approved some 
pharmacogenomics tests and published the guidance for genomic data 
submissions, which indicates a supportive approach to personalized drug 
therapy 118. The evaluation of the usefulness of genotyping has been 
recommended and prognostic values were suggested as important indicators 
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to assess 41, 46. The nature of prognostic values usually evaluated is 
described in section 3.3.4 and were determined in Paper III.  
 
 
Therapeutic drug monitoring (TDM) refers to measurement of drug plasma 
levels in the clinic with the aim of adjusting the dose or intervening with 
respect to adherence counselling or switching therapy 121. As described in 
sections1.5.3.3 and 1.7, EFV exhibits high inter-individual variability in 
plasma levels that may pre-dispose patients to either CNS toxicity or 
treatment failure. Since there is no sufficient evidence to support an increase 
in dose of EFV to 800 mg/day in HIV/TB co-infected patients, TDM was 
suggested as a useful tool in order to closely monitor EFV plasma levels and 
adjust the dose when proven necessary 11, 42.  
 
TDM remains a tool for therapy optimization for selected indications. 
However, implementing TDM requires the availability of validated and 
simple quantification assays with high selectivity, small sample volume 
requirements, and rapid turnaround time for the measurements. In addition, 
the assay needs to be cost-effective in order to guarantee its sustainable use in 
resource limited settings 45, 74. In Paper I, a selective and rapid analytical 
method suitable for the quantification of EFV in less resourced settings was 
developed. 
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This thesis aimed at contributing to the optimization of HIV therapy in the 
context of HIV and TB co-treatment by investigating the pharmacokinetic 
and pharmacogenetic aspects of EFV plasma levels in the absence and 
presence of rifampicin-based TB therapy (RBT). 
 
Specific aims were to:    
 
 develop and validate a rapid and selective analytical method for the 
quantification of EFV in human plasma containing first line 
medications used for the management of both HIV/AIDS and TB, 
and the major metabolites of EFV and rifampicin. (Paper I) 
 
 obtain pharmacogenomic data in a Rwandan population in genes 
coding for proteins involved in the metabolism of commonly used 
anti-infectious drugs, including antiretrovirals. (Paper II) 
 
 investigate the effects of 10 SNPs in five drug-metabolizing enzymes 
on EFV plasma levels and treatment response in the absence and 
presence of RBT. (Paper III) 
 
 investigate the predictive factors of EFV plasma levels and the 
prognostic values of CYP2B6 genotyping in predicting supra-
therapeutic EFV levels in the absence and presence of RBT. (Paper 
III) 
 
 evaluate the effects of RBT on EFV plasma levels and on the clinical 
response. (Paper III) 
 
 estimate the clearance of EFV in patients under both HIV and TB 
treatments by accounting for CYP2B6 genetic polymorphism and for 
DDIs caused by enzyme induction arising from both treatments. 
(Paper IV) 
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The high performance liquid chromatography (HPLC) instrument was an 
Agilent 1260 Infinity LC system consisting of a thermostated Hip-ALS 
autosampler, a binary pump, a degasser, and a thermostated column 
compartment. Analytes were monitored using an ultra-violet (UV) detector 
(SPD-10A, Shimadzu, Japan). Clarity Chromatography Data Station (CDS) 
(www.dataapex.com) was the software package used for system control and 
acquisition of EFV data during bioanalysis. 
 
 
Since EFV is a weak acid 122, reversed phase liquid chromatography was 
chosen using a C18 column. Ritonavir was selected as internal standard (IS) 
because the compound exhibits good UV absorbance and is well separated 
from EFV. 
 
The aim was to develop and validate a rapid and selective method in the 
presence of HIV/AIDS and TB medications, but also using at the same time 
an extraction procedure and a mobile phase that are straightforward. The 
extraction procedure employed was based on protein precipitation with 
acetonitrile containing the IS followed by sample centrifugation. The mixture 
acetonitrile:water (80:20 % v/v) at a flow-rate of 0.3 ml/min was selected as 
mobile phase for initial experiments while working with stock solutions. The 
injection volume was 10 μL. The post run time was set to 1 minute to allow 
for equilibration prior to injection of the next sample. EFV and ritonavir (IS) 
were monitored with the UV detector set at 247 nm.  
 
During method development, the proportions (% v/v) of the ingredients in the 
mobile phase were considered as adequate based on producing good peak 
resolution between the IS and peaks in blank plasma, and reproducibility of  
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the analyte response. Without trying the addition of new chromatographic 
modifiers, the proportions of the initial mobile phase (acetonitrile:water) 
were continuously modified, together with adjusting the pH (varying 
concentrations of formic acid) and the flow rate, until these criteria were met. 
The analysis time was progressively adjusted during the experiment and after 
obtaining a satisfactory mobile phase, chromatographic conditions were re-
adjusted to shorten the analysis time as much as possible.  
 
 
Validation of the method was carried out in terms of linearity, lower limit of 
quantification, selectivity, accuracy, precision, recovery and stability (at 
room temperature, during freeze–thaw cycles and heat application), in 
accordance with FDA bioanalytical method validation guidelines 123.  
 
 
Final chromatographic conditions were tested by analysing seven plasma 
samples collected from a representative patient co-infected with HIV/AIDS 
and TB, enrolled in the clinical study described in sections below. The patient 
was treated with EFV-based HAART (TDF+3TC+EFV) (EFV dosed 600 
mg) concomitantly with TB combination therapy (RHZE). Blood samples 
were collected between 0 and 8 hours after oral administration of EFV-based 
HIV treatment (EFV dosed 600 mg) to a patient on TB drugs since six weeks. 
Plasma samples were heated for 60 min at 56°C to inactivate HIV virus.  
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An open-label clinical study was conducted among adult HIV/AIDS patients 
co-infected with TB, receiving standard treatments, according to national 
treatment guidelines. Naive HIV patients initiating a standard TB treatment 
(HIV treatment deferred) were recruited. In addition, previous exposure to 
HIV treatment was allowed as in the previous design by ter Heine et al. 
(2008) 124. The study involved scheduled weekly visits to the clinics for 
blood sampling and patient follow up. Participating patients were monitored 
before, during and after the intensive initiation phase of TB therapy on a 
weekly basis. Genotyping was performed for all participants. EFV plasma 
concentrations, viral load and CD4 cell counts were measured throughout the 
study. This study was conducted in Rwanda at four sites throughout the 
country. The recruitment of patients started on August 15
th
, 2009 and the 
follow up occasions were concluded in November 2010. 
 
 
3.2.2.1 Nature of medications 
Medications were administered in accordance with the Rwandan guidelines 
for the management of HIV/AIDS 125.  HAART combination was 
composed of one NNRTI and 2 NRTIs. The NNRTIs used by participating 
patients were EFV (76 patients) and NVP (4 patients), while the combination 
of 2 NRTIs was 3TC plus either AZT or abacavir or stavudine or TDF. TB 
treatment consisted of the following rifampicin-based fixed dose-combination 
regimen: 2(RHZE)7/4(RH)3 (for the meaning of letters, numbers before the 
letters and subscripts, refer to section 1.3.2.2). Streptomycin which is 
normally indicated when one of these drugs is contraindicated 5 was given 
to only 8 patients of this cohort. Both treatments were administered in a pre-
existing directly observed therapy (DOT) program.  
 
3.2.2.2 Adherence to medications 
Adherence to the treatments was assessed at each weekly visit by means of 
patient self-report. The patient received a diary and was explained how to use 
it, writing down the date and time of every dose intake. The diary was 
brought to the clinic at every visit, where the Investigator asked the patient 
adherence related questions to assess the accuracy of the diary records.  
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In order to be eligible for inclusion, a patient (male or female) had to fulfil all 
of the following criteria: adults (21-65 years of age), HIV antibody positive 
with newly diagnosed HIV (naive) or on an HIV regimen, diagnosed for TB, 
anti-tubercular naive, literacy in the native language (Kinyarwanda), English 
or French, and provision of signed informed consent. The presence of any of 
the following was used as exclusion criteria from entry into the study: any 
clinically significant laboratory value or any known concurrent disease likely 
to limit life expectancy to less than 6 months, concomitant medication taken 
less than 14 days prior to the study that is known to cause interactions with 
the study medication, participation in another clinical drug trial within 3 
months prior to or during the study, and factors suggesting inability to 
comply with the protocol. Withdrawal criteria were voluntary decision of the 
patient to discontinue the participation in the study, decision of the 
Investigator to exclude the patient based on the patient health status or due to 
severe protocol violation. The reason for and date of subject removal from 
the study were documented in the Case Report Form (CRF).  
 
 
One hundred forty seven adult HIV/AIDS patients co-infected with TB were 
screened. One hundred and five patients who met inclusion criteria were 
recruited. Twenty five patients were withdrawn from the study during the 
follow up period in accordance with the study protocol. Eighty patients who 
completed the study were genotyped. Of these, four patients had been treated 
with NVP-containing therapy and were excluded from EFV studies; the 
remaining 76 patients had received EFV-based therapy. Among them, were 
naive patients who initiated RBT, with HAART to be initiated after two to 
eight weeks if CD4 cell counts were below 500 cells/µL, in accordance with 
the local treatment guidelines (Group A; n=41). A second category was 
composed of patients who were diagnosed for TB after several months of 
HIV treatment (Group B; n=35) and had immediately initiated RBT with 
HAART continuing. Schematic representations of the flow of the recruitment 
process of the patients and the study design are depicted in figure 2 and 
figure 3, respectively.  
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Figure 2. A schematic representation of the flow of the recruitment process 
of the patients. 
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Figure 3. Schematic illustration of the study design, including occasions for 
                treatment initiation and sampling. 
 
 
Patients had taken an EFV dose (600 mg) in the evening as per the current 
treatment guidelines. Samples were collected in the morning at arrival at the 
clinic, at the convenient time of the patient, approximately 13 hours after the 
previous evening EFV dose. Mid-dose sampling (sampling performed 
between doses, usually between 8 - 20 hours) was used because it is usually 
used in clinical studies of EFV disposition for patient convenience, given that 
EFV dose is invariably taken at bedtime. In addition, mid-dose levels of EFV 
have been reported to be highly associated with EFV area under the curve 
values when measured at steady state 74, 111.  
 
3.2.5.1 Baseline visit  
The day of initiation of TB treatment was the day of enrolment in the study. 
At enrolment after the obtainment of the patient´s written informed consent,  
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demographic variables (patient gender, age and body weight) were recorded, 
and blood samples collected for baseline clinical chemistry tests (alanine 
transaminase -ALAT-, aspartate transaminase -ASAT-, total bilirubin), and 
baseline CD4 cell counts and viral loads. An additional blood sample was 
collected at enrolment for genotyping.  
 
3.2.5.2 Sparse sampling 
After initiation of both HIV and TB treatments, patients were monitored on a 
weekly basis to collect blood samples for determination of EFV and 
treatment response data (CD4 cell counts and HIV-RNA copies). EFV was 
monitored over six weeks following the initiation of HAART. An additional 
sample was collected after at least two weeks of completion of TB treatment 
(n=25) (Figures 2 and 3). 
 
3.2.5.3 Rich sampling 
At initiation of the treatment after enrolment, rich sampling was performed at 
pre-dose and after 1, 2, 3, 4, 6 and 8 hours of initiation of HAART (Figures 2 
and 3). 
 
3.2.5.4 Blood sample handling 
All blood samples were collected into ethylene diamine tetra-acetic acid 
(EDTA)-containing tubes (4 ml), stored first at −30°C in clinics for one 
week, and then transferred at −80°C until analysis. Samples for determination 
of EFV concentrations were centrifuged (10 minutes at 10500 g) before 
storage. On the day of analysis, plasma samples were heated for 60 min at 
56°C to inactivate HIV virus, using the technique described elsewhere 126, 
127. 
 
3.2.5.5 Defining the data used 
Blood samples collected in patients taking concomitantly HIV treatment and 
RBT were used for determination of EFV in the presence of TB drugs. EFV 
plasma concentrations in the absence of TB drugs (data for EFV alone) were 
quantified in blood samples collected after at least two weeks of completion 
of TB therapy. Data were considered as complete for each patient when one 
of the variables to use was not missing (plasma concentration or genotype, or 
HIV-RNA copies or CD4 cell counts, depending on the envisaged 
investigation). In each analysis, only patients with complete data were 
considered. 
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3.2.6.1 Bioanalysis for the quantification of efavirenz 
EFV was quantified in the Unit for Pharmacokinetics and Drug Metabolism, 
Department of Pharmacology of University of Gothenburg, using a 
developed and validated high-performance liquid chromatography method 
with ultraviolet detection as described in Paper I.  
 
3.2.6.2 Genotyping 
Patients were genotyped using a PCR-based technology with respect to 13 
SNPs; CYP1A2 (-739T>G, -163C>A, -729C>T and 2159G>A); CYP2A6 
(479T>A, 1436G>T, -48T>G and 1093G>A); CYP2B6 (516G>T, 785A>G 
and 983T>C); CYP3A4 (-392A>G) and CYP3A5 (6986A>G). The 
background, genotyping methodology and findings including the frequency 
of alleles, genotypes and haplotypes are described in Paper II. 
 
3.2.6.3 CD4 cell counts and plasma HIV-RNA quantification 
CD4 cell counts were determined using FACS Count System (Becton 
Dickinson, San Jose, CA, USA) at the Butare University Teaching Hospital 
Laboratory in Rwanda. Plasma HIV-RNA was quantified using the COBAS 
Amplicor, version 2.0 (Roche Diagnostics, Branchburg, NJ) at the 
Department of Infectious Diseases of University of Gothenburg. The lower 
detection limit for HIV-RNA level was 50 copies/mL. 
 
 
The clinical study was conducted in accordance with the principles laid down 
in Helsinki Declaration of 2008, and the ICH (International Conference on 
Harmonization) guidance for Good Clinical Practice. Prior to inclusion in the 
study, patients were given full and adequate verbal and written information 
regarding the nature of the study and explained that participation in the study 
is voluntary. All information regarding participating patients (e.g. the 
patient’s identity) was kept confidential during data analysis and reporting. 
Ethics approval was sought from and given by the National Ethics 
Committee of the Ministry of Health in Rwanda on December 9
th
, 2008 for 
12 months, and was renewed on December 12
th
, 2009 for another 12 months. 
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The source data was the Case Report Form (CRF).  Results on lab-report 
printouts were immediately transferred into the CRF to avoid missing some 
data or later confusions of data. Hospital records were consulted whenever 
needed.  
 
Adherence to the protocol and the accuracy of records in the CRFs were 
monitored on a regular basis, and facilities at study sites checked regularly. 
Patient visits to the study clinics were scheduled within each week in a way 
allowing the study coordinator to be present at each site the days of patient 
visits in order to allow providing the study personnel with support and 
advice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Emile Bienvenu 
30 
 
 
 
The statistical tests were selected according to whether the data were 
normally distributed or not, whether the analysis involves two or more than 
two sample groups, and whether they were independent or not. The data to be 
investigated (EFV plasma levels, HIV-RNA copies, CD4 cell counts) were 
first tested for normality using the Shapiro-Wilk test. A p-value <0.05 was 
considered to be statistically significant. Predictive Analytics SoftWare 
(PASW) Statistics 18 (Chicago, IL) was used to perform statistical analyses. 
 
3.3.1.1 Assessment of relationships between variables 
The Spearman’s correlation by rank was used to measure statistical 
dependence between dependent and independent variables studied. 
Investigating whether independent variables were associated with the 
dependant variable (EFV levels in our case) was performed using non-
parametric tests, Kruskal-Wallis and Mann-Whitney for groups of three and 
two, respectively, if the data for the dependant variable were non-normally 
distributed and unrelated; and using one-way analysis of variance (ANOVA) 
followed by Tukey's multiple comparison test if the data for the dependant 
variable were normally distributed. EFV data were log-transformed when 
necessary. For prediction analyses aiming at investigating whether various 
independent variables could predict the dependant variable, regression 
analysis was performed. Other specific non-parametric tests were used where 
appropriate (Pearson chi-square (2) and Fisher's exact test).  
 
In this thesis: 
- Pearson 2 test was used to perform Hardy–Weinberg equilibrium 
(HWE) analysis by comparing expected and observed genotype 
frequencies for SNPs during genotyping (Paper II). 
- Fisher's exact test was performed to investigate the differences between 
populations with regards to allele and genotype distributions (Paper II). 
- The Spearman’s correlation by rank was used to assess correlations 
between EFV plasma levels and patient baseline characteristics 
(Paper III). 
- The association of genotype groups with EFV levels was performed 
using Kruskal-Wallis test for groups of three, followed by Mann-Whitney 
test for pairwise comparisons. Mann-Whitney test was also used where 
only two genotype groups were present (Paper III).  
Optimization of HIV therapy in patients co-infected with tuberculosis 
 
31 
- One-way ANOVA followed by Tukey's multiple comparison test was 
used to compare log10 EFV plasma levels over the six weeks of follow 
up (Paper III).  
- Linear regression analysis was used to determine the predicting effects 
of patients’ baseline characteristics and genotypic variants and their 
contribution to overall variability in EFV plasma levels (Paper III). 
 
In performing the regression analysis, genotypes were dichotomized 
according to the dominant genetic model (wild-type = 0; 
heterozygote/homozygote variants = 1) 129, as shown under Table 4. 
Univariate analyses of the effects of patients’ baseline characteristics and 
CYP enzyme genotypes on log10 EFV levels (dependant variable) were 
assessed by linear regression. The percentage change in EFV plasma levels, 
with the 95% confidence interval (CI), was calculated as 100 x regression 
coefficient. Multivariate regression analysis, using a stepwise backward 
elimination method, was conducted by including variables that achieved 
statistical significance in the univariate analyses. To avoid confounding 
effects on the relation between selected genotypes and the end-points, 
covariates that had a p-value of less than 0.20 in univariate analyses were 
included in the multivariate analyses. Plasma levels of EFV were log-
transformed in order to achieve data normality for the linear regression 
analysis and equal variance.  
 
3.3.1.2 Comparison of related samples 
Two related sample groups were compared using Wilcoxon signed-ranks test 
if the data were non-normally distributed, and paired sample t-test if the data 
were normally distributed. In order to assess the effect of RBT on EFV 
plasma levels and clinical response (Paper III), within-patient comparisons 
were conducted using: 
- Wilcoxon signed-ranks test to compare  
o EFV levels with and without RBT, and  
o HIV-RNA copies at baseline and after six weeks of HAART; 
- Paired sample t-test to compare CD4 cell counts at baseline and after six 
weeks of HAART. 
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When genotyping, the extent to which association mapping can be used in a 
population needs to be determined. Linkage disequilibrium (LD) measures 
the degree to which SNP alleles at two or more sites in the same region of the 
genome are associated. In a population, two linked SNP alleles occur at a 
frequency higher or lower than expected on the basis of the gene frequencies 
of the individual genes. If SNP alleles at the two sites are not randomly 
associated, then there will be a deviation (D’) in the expected frequencies. 
The parameter D’ is the coefficient of LD. D’ varies between 0 and 1 and 
allows assessing the extent of linkage disequilibrium relative to the maximum 
possible value it can take. If D’=0, then the two sites are in linkage 
equilibrium, meaning that the genotype present at one site is independent of 
the genotype at a second site. If D’≠0, the two sites are in LD indicating that 
genotypes at the two sites are not independent of another (dependency). 
LD=1 implies that the markers (genotypes) provide exactly the same 
information. When LD=1, the two sites are said to be in complete or tight LD 
128, 129. LD analysis was performed using SHEsis software platform in 
order to evaluate the degree of association between SNPs which were 
selected for genotyping the population studied (Paper II). 
 
 
When carrying out genotyping, the quality of the assay needs to be validated. 
Hardy-Weinberg equilibrium is a common criterion with which to assess the 
quality of a genotyping assay 130.The Hardy–Weinberg principle states that 
both allele and genotype frequencies in a population remain constant which 
mean that they are in equilibrium, referred to as Hardy-Weinberg equilibrium 
(HWE). Under HWE, alleles segregate randomly in the population, allowing 
expected genotype frequencies to be calculated from allele frequencies. A 
comparison of the expected and observed genotype frequencies provides a 
test of HWE; deviation from HWE is generally tested for by using the 
Pearson chi-square (2). Thus, the degree of deviation from HWE indicates 
the quality of genotyping. A p-value below a pre-determined threshold 
indicates a deviation from HWE 129. The deviation from HWE was tested 
for all the SNPs when genotyping the population studied, using Pearson 2 
test (Paper II).  
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In clinical practice, prognostic values are usually evaluated before 
introducing a diagnostic technology. Methods for evaluating a disease or a 
characteristic are compared against a gold standard, which is the best or the 
preferred method of diagnosing a particular disease or a characteristic 119. 
Usually evaluated prognostic values are the clinical sensitivity, specificity, 
negative (NPV) and positive (PPV) predictive values.  
 
The PPV is the proportion of patients with positive test result who actually 
have the disease or the characteristic, whereas the NPV is the proportion of 
patients with a negative test result who do not have the disease or the 
characteristic 119, 120. The PPV indicates the chance of having the disease 
or the characteristic among those that test positive, while the NPV indicate 
the chance of not having the disease or the characteristic among those that 
test negative 119, 120. The clinical sensitivity (proportion of patients that 
are known to have the disease/characteristic and are tested positive for it) and 
the clinical specificity (proportion of patients that are known not to have the 
disease/characteristic and are tested negative for it). Using the methods 
adapted from Sackett et al., (1991) 119, these prognostic values were 
determined in Paper III to assess the validity of CYP2B6 genotyping in 
predicting EFV plasma levels above the upper limit of the therapeutic range 
(4 g/ml), which was the characteristic to be evaluated.  
 
 
The population PK analysis was performed in NONMEM computer program, 
Version 7.1.2 and goodness-of-fit plots were constructed with Xpose4 library 
(version 4.3.2, 2010) run in R program (version 2.13.0, 2011). A one-
compartment model with first-order absorption and elimination was used to 
describe the data, using the NONMEM subroutine ADVAN5/TRANS1 and 
first order conditional estimation (FOCE) method. Inter-individual variability 
(ω2) was estimated for all the structural parameters of the model using an 
exponential error model, assuming that the individual value for a structural 
parameter was log-normally distributed. Residual variability (σ2) was 
estimated as an additative residual error on log-transformed data 
corresponding to an approximately exponential residual model. 
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Population PK parameters including CL/F, V/F and Ka with a lag time (alag) 
were first estimated in the basic PK model. CL/F values were estimated at  
baseline and at steady state to take into account the potential for the previous 
treatment to induce EFV metabolism. CL/F at baseline corresponded to the 
CL/F of the first day of initiation of HAART for group A patients (naive) 
after some weeks of RBT, and the CL/F at the day of enrolment in the study 
after several months of EFV-based HAART in group B patients. CL/F at 
steady state corresponded to the CL/F estimated for the two patient groups 
over six weeks with patients being under concomitant HIV and TB 
treatments. Different CL/F for each of the three CYP2B6 516G>T genotypes 
were estimated in the two groups in order to quantify the impact of genetic 
polymorphism in that gene on the metabolism of EFV. The CL/F at baseline 
and at steady state was modelled according to the following equations:  
At baseline (time = 0): )exp(*/ iFiCL   
At steady-state (time>0): )exp(*)1(*/ iFractFiCL    
Where CL/Fi is the apparent clearance of the i
th 
individual;  is the typical 
value of clearance in the population; i is the inter-individual variability in 
clearance; and Fract represents the fractional increase in baseline clearance.  
 
The final model selection was based on standard goodness-of-fit plots, 
agreement in the observed and individual and population predicted data, lack 
of trend or pattern in scatter plots of weighted residuals versus predicted 
concentrations or conditional weighted residuals versus time, the precision of 
the parameter estimates expressed as relative standard error (%RSE), based 
upon the known PK of EFV, agreement between the observed data and the 
95% confidence interval (CI) of the data and comparison of NONMEM 
objective function values (OFV; it is expressed for convenience as minus 
twice the log of the likelihood, and is a single number that provides an 
overall summary of how closely the model predictions match the data; the 
lower the OFV, the best the fit). A reduction in OFV of at least 3.84 was 
considered significant (p = 0.05). Model validation was performed using 
bootstrap with 200 re-sampled datasets, and a simulation-based visual 
predictive check (VPC) to evaluate whether model predictions adequately 
described the observed data 131 (Paper IV). 
 
 
 
 
 
 
 
Optimization of HIV therapy in patients co-infected with tuberculosis 
 
35 
 
 
Chromatographic conditions 
Chromatographic separation was performed using a C18 (100 × 4.6 mm, 2.6 
μm particle size) analytical column equipped with a short guard column 
(Kinetex

, Phenomenex

, Torrance CA, USA). A reversed phase isocratic 
elution of the analytes was achieved using a mobile phase consisting of 25% 
solvent A (Milli-Q water; pH adjusted at 3.2 using 0.1% formic acid) and 
75% solvent B (acetonitrile), pumped at a flow rate of 0.3 ml/min at ambient 
temperature. The analysis time was 6 min. The lower limit of quantification 
was set to 0.06 g/mL with deviation from the nominal concentrations being 
<20%, in accordance with FDA bioanalytical method validation guidelines 
123.  
 
Validation parameters 
- Linearity: the response was linear with a correlation coefficient of 
0.9997, a slope of 0.189 and an intercept of 0.003. The relative 
standard deviation for the slope was 5.474%.  
- Accuracy and precision: the accuracy ranged between 98 and 115% 
(intraday) and between 99 and 117% (interday). The precision ranged 
from 1.670 to 4.087% (intraday) and from 3.447 to 13.347% 
(interday). 
- Recovery and stability: the recovery ranged from 98 to 132%, and the 
stability between 99 and 123%.  
- Selectivity: the selectivity was demonstrated by the analysis of drugs 
used for the management of HIV/AIDS and TB, and the major 
metabolites of EFV and rifampicin. Obtained retention times (Rt) are 
given in table 1.  
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Table 1. Retention times of drugs commonly used in the  
Treatment of HIV/AIDS and TB, and metabolites of EFV  
and rifampicin.
 
Adapted from Paper I. 
 
 Drug Retention time
*
 (min) 
Antiretrovirals Abacavir 3.3 
 Lamivudine 3.2 
 Nevirapine 3.6 
 Stavudine 3.1 
 Tenofovir 3.1 
 Zidovudine 3.4 
TB drugs Ethambutol
c
 - 
 Izoniazid 3.1 
 Pyrazinamide 3.2 
 Rifampicin 3.4 
 Streptomycin
c
 - 
Adjuvant drugs Pyridoxin 3.0 
 Sulfamethoxazole
c
 - 
 Trimethoprim 3.0 
Metabolites 8-hydroxy-
Efavirenz 3.3 
 Deacetyl-
Rifampicin 3.5 
*Retention times of drugs listed in this table were compared to those  
of EFV (5.6 minutes) and ritonavir  (IS) (4.6 minutes). 
 cNot detected by UV 
 
Ethambutol, streptomycin and sulfamethoxazole were not detected by the 
current method due to their lack of absorption in UV. All other drugs were 
well separated from the analytes (EFV; Rt = 5.6 min) and IS (Rt = 4.6 min). 
This is also illustrated by a representative chromatogram from a plasma 
sample collected 3 hours after oral administration of EFV-based treatment 
from a patient on concomitant treatment of HIV and TB (Figure 4). The data 
demonstrated no interference from co-medications with the peak of EFV and 
IS, respectively. 
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Figure 4. A representative chromatogram from a plasma sample collected 3 
hours after oral administration of efavirenz-based treatment (EFV dosed 600 
mg) from a patient on concomitant treatment of HIV and TB. From Paper I. 
 
Application of the method 
The method was applied by analyzing plasma samples containing HIV and 
TB drugs as described in the section 3.1.4. A representative chromatogram 
from a plasma sample collected 3 hours after oral administration of EFV-
based treatment is shown in figure 4.  
 
The reported HPLC-UV method quantitated EFV in relatively short time (6 
minutes) and used a mobile phase and plasma extraction procedure that were 
straightforward. The extraction procedure produced clear supernatants from 
human plasma with no interference from endogenous compounds and both IS 
and analyte completely resolved to baseline. HPLC using UV is, due to lower 
cost and greater robustness, still widely used for relatively less complex 
bioanalytical assays 132. Several analytical methods have previously been 
reported for the determination of EFV in human plasma using HPLC-UV 
133-135. However, some HPLC-UV methods use procedures resulting in 
long analysis time 132, 134, 136, 137, hence limiting the scopes of their 
application.  
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Furthermore, the selectivity of this method was tested in the presence of a 
wide range of medications used for the management of HIV/AIDS and TB, 
specifically all first line antiretrovirals and TB drugs, as well as other 
medications used as adjuvant to HIV/AIDS and TB therapies, and the major 
metabolite of EFV (8-hydroxyefavirenz) and rifampicin (deacetyl-
rifampicin). The chromatography yielded a well-resolved EFV peak without 
interference from co-medications with the detection process of the analyte. 
Indeed, published methods have studied the interference of only some TB 
drugs, without testing interference from other medications used as adjuvant. 
No data demonstrating a lack of interference of EFV and rifampicin 
metabolites with the parent drugs when using HPLC-UV are available, while 
metabolites may interfere when analyzing parent drugs 138. The reported 
method was characterized by a high selectivity allowing its applicability in 
the quantification of EFV from HIV/TB patients. 
 
In comparison to several other published methods for the quantification of 
EFV, the reported HPLC method presents the advantage of being 
simultaneously rapid, selective in the presence of a wide range of HIV and 
TB medications, and straightforward by using a mobile phase and extraction 
procedure that are simple. Therefore, this HPLC method is suitable not only 
for PK studies, but also for TDM in patients with HIV/AIDS alone or co-
infected with TB at sites with less resourced settings. 
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Allele and genotype frequencies showed genetic variation in a Rwandan 
population 
 
Genetic variation was observed in 11 of the 13 SNPs with two being 
monomorphic (CYP1A2 -729C>T and CYP2A6 479T>A). These two 
monomorphic SNPs presented with a single allele each (C for CYP1A2 -
729C>T and T for CYP2A6 479T>A); consequently only one genotype 
group for these SNPs could be identified (Table 2). The minor allele 
frequencies (MAF) were identified for 10 SNPs, such as CYP1A2 -739G, 
CYP1A2 2159A, CYP2A6 1436T, CYP2A6 1093A, CYP2A6 -48G, 
CYP2B6 516T, CYP2B6 785G, CYP2B6 983C, CYP3A4 -392A and 
CYP3A5 6986G (Table 2). Positions -739 and -163 in CYP1A2 gene and 
positions 516 and 785 in CYP2B6 gene were in complete LD (coefficient of 
LD = 1.000). All the SNPs conformed to HWE. Haplotypes were also 
inferred; results are shown in table 3.  
 
Differences to other African populations 
A comparison of allele and genotype frequency between the Rwandan 
population studied and other African populations revealed significant 
differences in the distribution of allelic variants when the Rwandan subjects 
were compared to Cameroonian and South African populations with respect 
to CYP2A6 1093G>A SNP (P=0.0033 and 0.019, respectively) and CYP3A4 
-392A>G SNP (P=0.0001 and 0.0084, respectively). There were differences 
in the distribution of the CYP1A2 -163C>A SNP between the Rwandan 
subjects and the South African population (P=0.0001), but not with the 
Cameroonian population (P=0.265).  The distribution of CYP3A5 6986A>G 
SNP differed between the Rwandan subjects and the Cameroonian population 
(P=0.017) but not with the South African population (P=0.097). The 
CYP2B6 516G>T polymorphism did not show significant differences 
(P>0.05) between the Rwandans, Cameroonians and South Africans in the 
distribution of the 516T variants. This is consistent with earlier results from 
Svärd et al. 21 and Kwara et al. 74, 139 who reported the high prevalence 
of the same allelic variants in other African populations. 
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Table 2. Allele and genotype frequencies in Rwandan subjects for selected SNPs. 
From Paper II. 
 
Gene Reference 
SNP 
SNP Allele Frequency 
(N) 
95% CI Genotype Frequency 
(N) 
95% CI 
CYP1A2 rs2069526 T-739G T 0.893 (125) 0.831-0.934 T/T 0.800 (56) 0.691-0.877 
 
 
 
G 0.107 (15) 
0.066-0.169 T/G 0.186 (13) 0.112-0.293 
 
 
  G/G 0.014 (1) 0.003-0.076 
 rs12720461 C-729T C 1.000  (140) 0.974-1.000 C/C 1.000 (70) 0.949-1.000 
 
 
 
T 0.000 (0) 
0.000-0.026 C/T 0.000 (0) 0.000-0.051 
 
 
  T/T 0.000 (0) 0.000-0.051 
 rs762551 C-163A C 0.559 (76) 0.475-0.640 C/C 0.324 (22) 0.224-0.442 
 
 
 
A 0.441 (60) 
0.360-0.525 C/A 0.471 (32) 0.356-0.588 
 
 
  A/A 0.025 (14) 0.127-0.317 
rs2472304 G2159A G 0.887 (126) 0.825-0.929 G/G 0.803  (57) 0.695-0.878 
 
 
 
A 0.113 (16) 
0.071-0.175 G/A 0.169 (12) 0.010-0.273 
 
 
  A/A 0.028 (2) 0.009-0.097 
CYP2A6 rs5031017 G1436T G 0.816 (111) 0.743-0.872 G/G 0.691 (47) 0.573-0.788 
 
 
 
T 0.184 (25) 
0.128-0.257 G/T 0.250 (17) 0.163-0.365 
 
 
  T/T 0.059 (4) 0.024-0.142 
 rs28399454 G1093A G 0.979 (137) 0.939-0.992 G/G 0.957 (67) 0.881-0.984 
 
 
 
A 0.021 (3) 
0.008-0.061 G/A 0.043 (3) 0.016-0.119 
 
 
  A/A 0.000 (0) 0.000-0.051 
 rs1801272 T479A T 1.000 (136) 0.973-1.000 T/T 1.000 (68) 0.948-1.000 
 
 
 
A 0.000 (0) 
0.000-0.027 T/A 0.000 (0) 0.000-0.052 
 
 
  A/A 0.000 (0) 0.000-0.052 
 rs28399433 T-48G T 0.899 (124) 0.837-0.938 T/T 0.811 (56) 0.703-0.886 
 
 
 
G 0.101 (14) 
0.062-0.163 T/G 0.173 (12) 0.103-0.280 
 
 
  G/G 0.014 (1) 0.003-0.077 
CYP2B6 rs3745274 G516T G 0.669 (91) 0.586-0.743 G/G 0.439 (29) 0.315-0.540 
 
 
 
T 0.331 (45) 
0.257-0.414 G/T 0.439 (29) 0.315-0.540 
 
 
  T/T 0.121 (8) 0.061-0.214 
 rs2279343 A785G A 0.667 (92) 0.584-0.740 A/A 0.449 (31) 0.337-0.567 
 
 
 
G 0.333 (46) 
0.260-0.416 A/G 0.435 (30) 0.324-0.553 
 
 
  G/G 0.116 (8) 0.061-0.213 
 rs28399499 T983C T 0.919 (125) 0.861-0.954 T/T 0.838 (57) 0.733-0.907 
 
 
 
C 0.081 (11) 
0.046-0.139 T/C 0.162 (11) 0.093-0.267 
 
 
  C/C 0.000 (0) 0.000-0.052 
CYP3A4 rs2740574 A-392G G 0.529 (74) 0.446-0.609 G/G 0.272 (19) 0.181-0.386 
 
 
 
A 0.471 (66) 
0.391-0.554 G/A 0.514 (36) 0.399-0.628 
 
 
  A/A 0.214 (15) 0.135-0.324 
CYP3A5 rs776746 A6986G A 0.703 (97) 0.622-0.773 A/A 0.478 (33) 0.364-0.594 
 
 
 
G 0.297 (41) 
0.227-0.378 A/G 0.449 (31) 0.337-0.567 
 
 
  G/G 0.073 (5) 0.032-0.159 
 
 
 
 
Optimization of HIV therapy in patients co-infected with tuberculosis 
 
41 
 
Table 3. Haplotype frequencies in Rwandan subjects for selected SNPs. From 
Paper II. 
 
SNPs Haplotype Frequency (N)  
CYP1A2 rs762551-rs12720461-rs2069526-
rs2472304 
A-C-G-G 0.099 (13) 
A-C-T-A 0.114 (15) 
A-C-T-G 0.220 (29) 
C-C-T-G 0.568 (75) 
CYP2A6 rs28399433-rs1801272-rs28399454-
rs5031017 
G-T-G-G 0.092 (12) 
T-T-G-G 0.703 (89) 
T-T-G-T 0.174 (22) 
T-T-A-G 0.020 (3) 
CYP2B6 rs3745274-rs2279343-rs28399499 
G-A-C 0.082 (11) 
G-A-T 0.605 (81) 
T-G-T 0.313 (42) 
 
The existence of single genotype groups for each of the two monomorphic 
SNPs implies same characteristics in the phenotype for all subjects carrying 
these genotypes in the cohort studied. The MAF observed showed alleles that 
appear less frequently than the others in this population. The SNPs in both 
CYP1A2 and CYP2B6 genes being in complete LD indicated a total 
dependency between these SNPs, as previously reported by Svärd et al. 21 
and Swart et al. 140. The observed genetic variation in the Rwandan 
subjects was also reported for other populations 140, 141. Genetic variation 
has been shown to influence both efficacy and safety of drugs, which is 
attributed to polymorphisms in the CYP gene family that confer rapid versus 
slow metabolizers of drugs 142. The clinical relevance of such genetic 
variations observed in the population studied needs to be explored further.  
 
In summary, the presented genomic information on a Rwandan population, 
especially in terms of genetic variation, indicates a need for further genomic 
and genotype-phenotype investigations to explore the clinical influence of 
polymorphisms in the CYP system and its relevance in the population 
studied. Differences observed between the Rwandans and other African 
populations are congruent with genetic diversity earlier reported for Africans. 
This suggests genomic screening for all African populations in order to be 
able to predict responses to drugs based on specific rather than general 
genetic data. 
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Highlights for population characteristics  
The gender ratio (male:female) was 1.05 (39:37) and the mean (range) age 
was 38.0 (21-57) years. Other baseline characteristics of the participating 
patients were described in papers III and IV.  
 
Highlights for EFV plasma levels  
The coefficients of variation within and between subject plasma levels were 
28% and 88%, respectively. 32% of the patients had plasma EFV levels 
outside the expected therapeutic range (1-4 g/ml) with 14% of these having 
plasma levels above 4 g/ml and 18% having plasma levels below 1g/ml, 
whereas 68% presented with plasma EFV levels within the expected 
therapeutic range. 
 
No correlation between population characteristics and EFV levels 
There were no statistically significant associations when baseline 
characteristics (patient gender, age, body weight, ALAT, ASAT, total 
bilirubin and baseline CD4 cell counts and viral loads) were compared to 
EFV plasma levels, whether when with or without concomitant RBT.  
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CYP2B6 516T/T genotype associated with high EFV levels 
With respect to CYP2B6 516G>T, EFV plasma levels significantly differed 
by genotype in the absence (P=0.006) and presence (P=0.0005) of RBT. 
Pairwise comparisons revealed that CYP2B6 T/T genotype was associated 
with high EFV plasma levels compared to G/G (P=0.009) and G/T (P=0.004) 
genotypes when EFV-based therapy was given alone (Figure 7A), and when 
it was given concurrently with TB treatment (P=0.00002 and 0.005, 
respectively; Figure 7B). When comparing follow up occasions during 
concomitant HIV and TB treatment, a significant difference in EFV plasma 
levels was observed between CYP2B6 516T/T genotype and the other two 
genotypes (G/T and G/G) (P=0.0001) over the six weeks of follow-up (Figure 
8C). Further, the analysis showed a statistically significant difference 
between CYP2B6 516G/T and G/G genotypes when patients were treated 
with EFV-based therapy combined with RBT (P=0.037; Figure 7B), but not 
when it was given alone (P=0.073; Figure 7A).  
 
 
 
Figure 7. Effects of CYP2B6 516G>T genotypes on EFV plasma levels when 
patients were treated with EFV-based therapy alone (A) and when it was 
combined with TB treatment (B). Boxes represent interquartile ranges; 
horizontal lines within boxes, median values.  and * indicate outlier and 
extreme values, respectively. Dotted lines represent the therapeutic window 
for EFV (1 – 4 g/ml). From Paper III. 
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Figure 8. Comparisons over the six weeks of follow up between 
CYP2B6 516G>T genotypes (C) and between CYP1A2 -739T>G genotypes. 
Over six weeks, CYP2B6 516T/T genotype was significantly different in EFV 
levels compared to G/T and G/G genotypes (C) (P=0.0001), and the 
difference between CYP1A2 -739T/G and T/T genotypes (D) was also 
significant (P=0.0001). From Paper III. 
 
 
Similar observations have been made in other cohorts, where high EFV levels 
in carriers of CYP 2B6 516T/T were observed, with examples among Thai 
143, 144, Caucasian 145 and South African patients 77. Since, EFV 
levels above the therapeutic range were found to cause CNS toxicity in HIV 
patients 11, 77-80, carriers of the CYP 2B6 516T/T genotype in the 
population studied treated with EFV-based HAART are at high risk of 
developing the same side effects. The same applies for carriers of 
CYP2B6 785G/G genotype due to the fact that 516G>T and 785A>G SNPs 
in CYP2B6 gene were in complete LD as discussed in section 4.2. 
 
CYP2B6 983T/T genotype associated with higher EFV levels  
There was no statistically significant difference between CYP2B6 983T>C 
genotypes (P > 0.05) when compared for the association with EFV plasma 
levels; over the six weeks however, the CYP2B6 983T/T genotype was 
associated with significantly higher EFV levels (P=0.0035) compared to T/C 
genotype. 
 
According to the present data, CYP2B6 983T allelic variant had a higher 
frequency (0.919; Table 2) in the Rwandan subjects. This was consistent with 
reports stating that CYP2B6 983T>C SNP is found not only in non-African 
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populations 147, 148, but also in African populations or in populations of 
African descent 74, 146. Since CYP2B6 983T>C SNP shares similar 
characteristics with CYP2B6 516G>T polymorphisms 74, 91 and since 
CYP2B6 516G>T polymorphisms has been associated with high EFV levels 
in the cohort studied as discussed above, it is possible that CYP2B6 983T>C 
SNP exhibits in some individuals the same trends in the phenotype as 
CYP2B6 516G>T. In other studies, CYP2B6 983T>C SNP has shown to be 
associated with elevated EFV plasma levels 46, 120 
 
Difference between CYP1A2 -739T/G and T/T genotypes only in the 
presence of RBT 
 
There was a significant difference between CYP1A2 -739T/G and T/T 
genotypes with respect to EFV plasma levels when patients were treated with 
EFV-based therapy combined with RBT (P=0.027; Figure 9F), but not when 
EFV-based therapy was given alone (P=0.145; Figure 9E). The difference in 
EFV levels between CYP1A2 -739T/G and T/T genotypes was also 
significant over the six weeks of follow up (P=0.0001; Figure 8D).  
 
 
 
Figure 9. Effects of CYP1A2 739T>G genotypes on EFV plasma levels when 
patients were treated with EFV-based therapy alone (E) and when it was 
combined with TB treatment (F). Boxes represent interquartile ranges; 
horizontal lines within boxes, median values.  and * indicate outlier and 
extreme values, respectively. Dotted lines represent the therapeutic window 
for EFV (1–4 g/ml). From Paper III. 
 
Given the scarceness of data concerning relationships between EFV exposure 
and SNPs in CYP enzymes other than CYP2B6, the present findings on 
CYP1A2 could not be compared with the data from other cohorts. CYP1A2  
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and CYP2A6 are part of the accessory pathways for EFV metabolism 30, 31, 
84. CYP1A2 participates in 8-hydroxylation of EFV together with other 
CYP enzymes with the rank order of CYP2B6 > CYP1A2 > CYP3A5 > 
CYP3A4 (Figure 2) 29. CYP2A6 gets involved in the second metabolic 
accessory pathway for 7-hydroxylation of EFV with the rank order of 
CYP2A6 > CYP2B6 (Figure 2) 30, 31, 84. di Iulio et al. (2009) 29 
reported a contribution of CYP2A6 alleles among individuals characterized 
as CYP2B6 slow metabolizers. Therefore, the present results indicating that 
the difference in association with EFV plasma levels between CYP1A2 -
739T/G and T/T genotypes becomes significant during concomitant treatment 
with RBT, hypothetically suggest that 8-hydroxylation of EFV may be 
redirected to CYP1A2 accessory pathway in slow CYP2B6 metabolizers. 
This shall be expected for CYP1A2 -163C>A given that -739T>G and -
163C>A in CYP1A2 gene were in complete LD as described in section 4.2 
above. It would be interesting to study the importance of these observations 
in larger groups. 
 
SNPs with no association with EFV levels 
No statistically significant associations were found between EFV plasma 
levels and the genotypes of the following SNPs, CYP1A2 (-163C>A, and 
2159G>A); CYP2A6 (1436G>T and -48T>G); CYP3A4 (-392A>G) and 
CYP3A5 (6986A>G) whether when with or without concomitant RBT.  
 
No association between genotypic variants and HIV treatment response 
There were no statistically significant associations between HIV-RNA copies 
and CD4 cell counts, and CYP1A2, CYP2A6, CYP2B6, CYP3A4 and 
CYP3A5 genotypes and haplotypes. 
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CYP2A6 1093G>A, CYP2B6 516G>T and CYP2B6 983T>C are 
independent predictors of EFV plasma levels 
 
Univariate linear regression analysis was conducted in order to determine the 
effects of patients’ baseline characteristics (gender, age, body weight, ALAT, 
ASAT, baseline CD4 cell counts, baseline viral loads, total bilirubin), and the 
genotypes with respect to the 10 SNPs, CYP1A2 (-739T>G, -163C>A, and 
2159G>A), CYP2A6 (1436G>T, 1093G>A and -48T>G), CYP2B6 
(516G>T, 983T>C), CYP3A4 (-392A>G) and CYP3A5 (6986A>G) as 
independent variables on log10 EFV plasma levels (dependant variable) 
collected from patients on concurrent HIV and TB treatment. Total bilirubin 
and the genotypes of CYP1A2 -739T>G, CYP2A6 1436G>T, CYP2A6 
1093G>A, CYP2B6 516G>T and CYP3A4 -392A>G SNPs statistically 
significantly predicted EFV levels (Table 4). Thus, they were included in the 
multivariate analysis.  The covariates that had a p-value of less than 0.20 
(CYP1A2 -163C>A and CYP2B6 983T>C) were also included to avoid 
confounding effects on the relation between selected genotypes and the end-
points.  Multivariate analysis was then performed to identify independent 
predictors of EFV plasma levels and to evaluate their contribution to overall 
variability in EFV plasma levels. Three independent variables with P<0.05 
remained in the final model, including CYP2A6 1093G>A (P=0.023), 
CYP2B6 516G>T (P=0.0004) and CYP2B6 983T>C (P=0.016; Table 4). The 
coefficient of determination (R
2
) for the regression was 0.302 (P=0.0002), 
indicating that the model explained 30% of the variability in EFV plasma 
levels. The standardized regression coefficients indicated that CYP2A6 
1093G>A, CYP2B6 516G>T and CYP2B6 983T>C accounted for 27%, 
43%, and 29% of the total variance in EFV plasma levels, respectively.  
 
The performed regression analysis identified CYP2A6 1093G>A and 
CYP2B6 983T>C as additional independent predictors of EFV levels beyond 
that provided by CYP2B6 516G>T polymorphism. Regarding the latter, its 
role in explaining variability in EFV levels has been previously reported 
extensively 11, 20, 43, 70, 76, 86-89, and the present data has also 
demonstrated its association with EFV levels in a Rwandan population, when 
with and without RBT as described in section 4.4 (Figure 7). As discussed in 
the same section, CYP2B6 983T>C SNP sharing similar characteristics with 
CYP2B6 516G>T polymorphisms 74, 91 could present with the same 
phenotypic trends as CYP2B6 516G>T. As described in section 4.4, 
CYP2A6 is part of the accessory pathways for EFV metabolism 30, 31, 84.  
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Its contribution to EFV metabolism among individuals characterized as 
CYP2B6 slow metabolizers has been also reported 29. In addition, an 
association between slow metabolizer CYP2A6 alleles and increased EFV 
concentration was mentioned by Kwara et al. (2009) 74. The current data 
suggest that CYP2A6 1093G>A and CYP2B6 983T>C SNPs have the 
potential to contribute to identifying patients who could be treated with 
adjusted dose of EFV through predictive genetic testing. Thus, in addition to 
CYP2B6 516G>T, genotypic data for CYP2A6 1093G>A and CYP2B6 
983T>C SNPs should be taken into consideration when estimating the 
appropriate dose of EFV for HIV patients. 
 
Table 4. Regression analysis of association between EFV plasma levels and 
influential factors. From Paper III. 
 
Independent variable % Log10 EFV (95% CI) 
p-value R
2
 
UNIVARIATE 
 
 
 Gender - 5.4 (- 20.6 to 13.5) 0.679 0.003 
Age (years) - 2.6 (- 1.2 to 1.0) 0.843 0.001 
Body weight (kg) 8.8 (- 0.6 to 1.3) 0.495 0.008 
Baseline CD4
*
 (cells/µL) 10.7 (- 0.03 to 0.1) 0.429 0.011 
Baseline log10 HIV-RNA
*
 
(copies/mL) 15.1 (- 2.6 to 8.7) 
 
0.289 0.023 
Alanine aminotransferase (U/ml) - 2.7 (- 0.4 to 0.3) 0.836 0.001 
Aspartate aminotransferase (U/ml) - 4.1 (-0.3 to 0.2) 0.749 0.002 
Total bilirubin (mg/dl)
 
 25.8 (0.3 to 15.6) 0.043 0.067 
CYP1A2 -739T>G 30.5 (4.6 to 44.7) 0.017 0.093 
 -163C>A 17.5 (-6.3 to 31.9) 0.186 0.031 
2159G>A 16.8 (-7.9 to 36.5) 0.203 0.028 
CYP2A6 1436G>T 27.6 (1.8 to 36.8) 0.031 0.076 
 1093G>A -28.8 (-100.1 to -7.5) 0.023 0.083 
 -48T>G 3.3 (-19.5 to 25.1) 0.805 0.001 
CYP2B6 516G>T 37.1 (8.6 to 40.6) 0.003 0.138 
983T>C 22.1 (-3.2 to 42.8) 0.090 0.049 
CYP3A4 -392A>G -28.2 (-41.9 to -2.7) 0.026 0.079 
CYP3A5 6986A>G -8.9 (-23.3 to 11.4) 0.494 0.008 
MULTIVARIATE 
 
0.0002 0.302 
CYP2A6 1093G>A -26.5 (-90.3 to -7.0) 0.023  
CYP2B6 516G>T 43.3 (13.5 to 44.4) 0.0004  
983T>C 28.7 (4.9 to 46.1) 0.016  
*
Refer to baseline before any HIV treatment, after enrolment. 
Genotypes were dichotomized and organized as follows: TT vs TG/GG for CYP1A2 -739T>G; CC 
vs CA/AA for CYP1A2 -163C>A; GG vs GA/AA for CYP1A2 2159G>A; GG vs GT/TT for CYP2A6 
1436G>T; GG vs GA/AA for CYP2A6 1093G>A; TT vs TG/GG for CYP2A6 -48T>G; GG vs GT/TT 
for CYP2B6 516G>T;  TT vs TC/CC for CYP2B6  983T>C; AA vs AG/GG for CYP3A4 -392A>G 
and for CYP3A5 6986A>G. 
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High PPV for CYP2B6 516T/T and 983T/T genotypes 
 
Sensitivity, specificity, PPV and NPV were evaluated to determine whether 
CYP2B6 SNPs could be used in predicting EFV plasma levels above the upper 
limit of the therapeutic range (Table 5). Overall, the predictive values for 
CYP2B6 SNPs were shown to change in the presence of RBT. Of note in this 
analysis was the higher PPV percentage (100%) for CYP2B6 516T/T and 
983T/T genotypes in the absence of RBT, which decreased in the presence of 
RBT by 3.3-fold for CYP2B6 516T/T genotype and by 1.4-fold for CYP2B6 
983T/T genotype. The latter genotype also had high specificity in the absence 
(100%) and in the presence (93%) of RBT. 
 
Table 5. Sensitivity, specificity and predictive values for CYP2B6 SNPs

 on 
EFV plasma levels. From Paper III. 
 
Genotype n Sensitivity (%) Specificity (%) PPV* (%) NPV* (%) 
In the absence of TB treatment 
CYP2B6 516G>T      
G/G 12 0.00 80.00 0.00 48.00 
G/T 13 0.00 81.25 0.00 52.00 
T/T 3 10.71 - 100.00 0.00 
CYP2B6 983T>C      
T/T 23 42.86 100.00 100.00 83.33 
T/C 4 0.00 57.14 0.00 16.67 
In the presence of TB treatment 
CYP2B6 516G>T      
G/G 28 3.85 75.00 10.00 51.92 
G/T 28 16.67 84.62 60.00 42.31 
T/T 6 5.77 30.00 30.00 5.77 
CYP2B6 983T>C      
T/T 50 50.00 93.48 70.00 86.00 
T/C 10 6.52 50.00 30.00 14.00 
Negative (NPV) and Positive (PPV) Predictive Values
*
 
 
CYP2B6 516G>T and 983T>C SNPs were shown to be independent predictors 
of EFV levels (section 4.5); beyond being associated with EFV levels (section 
4.4). Both 516G>T and 983T>C share similar characteristics, suggesting similar 
phenotype 74, 91. In addition, the results in section 4.2 demonstrated that 
CYP2B6 516G>T and 785A>G were in complete LD. Given this demonstrated 
relationship between EFV plasma levels and CYP2B6 SNPs in the population 
studied, the observed higher PPV for CYP2B6 516T/T and 983T/T genotypes in 
predicting supra-therapeutic EFV plasma levels is suggestive of predictive 
genetic genotyping for CYP2B6 SNPs to identify patients who could be at risk of 
CNS toxicity and need adjusted EFV dose. 
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EFV plasma levels were significantly lowered in the presence of RBT 
The effect of RBT on EFV plasma levels was assessed to determine whether 
variability in EFV plasma levels in the cohort studied is due to genetic 
polymorphism and RBT, and to assess its impact on the clinical response. 
The effect of RBT on EFV plasma levels was evaluated by comparing EFV 
levels measured from samples collected during concomitant HIV and TB 
treatments with those collected from the same patients after completion of 
RBT. Overall, compared to when EFV was alone, EFV plasma levels were 
lowered during concomitant HIV and RBT for 80% of patients.  The medians 
(IQR) EFV plasma levels were 2.7 (1.5-3.1) g/ml and 1.8 (1.4-2.3) g/ml in 
the absence and in the presence of RBT respectively, corresponding to a 
statistically significant decrease (P=0.004) of EFV plasma levels by 1.5-fold, 
following concomitant use of RBT (Figure 10G).  
 
The observed decrease of EFV plasma levels could partly be attributed to the 
reported induction effect of rifampicin on metabolizing enzymes of EFV as 
discussed in section 1.6.2, but also to overlapping EFV auto-induction. 
However, based on the data from his study cohort when HIV and TB were 
treated concomitantly, Ngaimisi et al. (2011) 12 demonstrated that EFV 
auto-induction does not exhibit significant additive or synergistic effects over 
and above ongoing RBT. This implies that a decrease of EFV levels observed 
in both groups of the cohort studied during HIV and TB co-treatment could 
be attributed mainly to RBT effects and to a non significant extent to EFV 
auto-induction. This is however to be confirmed in other prospective study 
cohorts. In line with the objective to ascertain whether both genetic 
polymorphism and RBT contribute to the variability in EFV plasma levels, 
the present data suggest that deciding on EFV dosages for HIV/TB co-
infected patients should take into accounts both CYP2B6 polymorphisms and 
RBT effects.  
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G H 
 
 
Figure 10. Changes in EFV plasma concentrations (g/ml) (G) and HIV-RNA 
(copies/mL) (H) after six weeks of initiation of antiretroviral therapy in the 
presence of TB treatment. In the presence of TB treatment, EFV plasma levels 
were statistically significantly lowered (P=0.004) and HIV-RNA copies were 
reduced significantly (P=0.002). Dotted, dashed and solid lines show carriers of 
CYP2B6 516T/T, G/G and G/T genotypes, respectively. From Paper III. 
 
 
Significant reduction in HIV-RNA copies in the presence of RBT 
Whether the statistically significant decrease in EFV levels in the presence of 
RBT had an impact on the treatment response was further explored. The 
effect of RBT on clinical response was evaluated by comparing HIV-RNA 
copies measured from group A patients (naive) at baseline and after six 
weeks of initiation of HAART in the presence of RBT. Only naive patients 
were included (Group A) to avoid bias that may be caused by patients 
enrolled in the study while they were previously on HAART (Group B).   
Wilcoxon signed-ranks test implied a statistically significant (P=0.002) 
reduction in HIV-RNA copies (median; IQR) from baseline (446407 
copies/mL; 83514 - 538809) to six weeks of initiation of HAART (328 
copies/mL; 141 - 7403) in the presence of RBT (Figure 10H), indicating no 
effect of the latter on the clinical response.  CD4 cell counts were increased 
in some patients and decreased in others and the difference was not 
statistically significant.  
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These data suggesting that viral loads decreased significantly in the presence 
of RBT are congruent with reports compiled by Avihingsanon et al. (2009) 
7 on lack of association between virological failure and decrease of EFV 
levels following concomitant use of RBT. The fact that significant reduction 
of HIV-RNA copies was not affected during co-medication with RBT 
suggests that taking into account TB treatment effects during dose adjustment 
could be made rather at individual than at population level. Specifically, the 
impact of RBT on EFV plasma levels could be assessed through TDM in 
patients suspected being at risk of sub-therapeutic levels and dictate dose 
adjustment only when the clinical response is affected. 
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Long term exposure to HAART increases the CL/F of EFV 
 
Oral clearance values of EFV were estimated using population PK modelling 
approach. The population CL/F values of the final model for EFV at baseline 
and at steady state stratified by CYP2B6 516G>T genotypes and by treatment 
nature are given in table 6. The fractional increases of CL/F were 0.51 and 
0.55 in patients who had initiated TB treatment prior to HAART and in group 
of those who had previous exposure to HAART for a long period (from 
weeks to years), respectively.  
 
Table 6. Population clearance of the final model for efavirenz by genotype 
and by nature of previous treatment. From Paper IV. 
 
 Parameter Estimate (%RSE
*
)
 
%IIV (%RSE
*
) 
 

TBPREV 

HAARTPREV  
CL/FG/G (L/h)  (a) 10.2 (14) 14.5 (10) 54 (37) 
                       (b) 15.4  22.5  
CL/FG/T (L/h) (a) 7.6 (15) 9.3 (16) 53 (33) 
                       (b) 11.5  14.4   
CL/FT/T (L/h)  (a) 3.4 (15) 1.6 (4) 32 (59) 
                      (b) 5.1  2.5   
CL/F: oral clearance stratified by CYP2B6 516 G>T genotypes, at baseline (a) and at steady 
state (b). IIV: Inter-individual variability. RSE: relative standard error. HAART: Highly Active 
Antiretroviral Therapy. TBPREV: Group of patients who had TB treatment prior to HAART. 
HAARTPREV: Group of patients who had previous exposure to HAART before being diagnosed 
for TB and initiation of its treatment. 
 *Estimated from bootstrap (n=200 samples). 
The fractional increases (%RSE) of CL/F were 0.51 (15.3) and 0.55 (9.6) in TBPREV group 
and in HAARTPREV group, respectively. 
 
As can be seen, the CL/F at baseline and steady state was always higher in 
patients with previous exposure to HAART (HAARTPREV) compared to those 
who were naive, and who initiated TB treatment prior to HAART (TBPREV). 
Exception to this was for carriers of CYP2B6 516T/T genotype; probably 
because of the limited sample size (only one T/T patient in the second group). 
As one could expect, carriers of CYP2B6 516G/G genotype (extensive  
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metabolizers) in all patient groups exhibited higher CL/F compared to 
carriers of other genotypes, whereas lower CL/F were seen with carriers of 
CYP2B6 516T/T genotype (poor metabolizers). The present results are in 
agreement with the trends of measured EFV plasma concentrations as plotted 
in figure 12, where patients with previous exposure to HAART showed lower 
concentrations compared to those who had prior TB treatment.   
 
The basic goodness of fit plots for the final PK model for EFV is shown in 
figure 13. Upper right and left plots show that observed concentrations match 
predicted concentrations, indicating that the suggested model described the 
PK of EFV adequately. Lower right and left plots show that residuals are 
evenly distributed around the reference line over time (constant variance). 
The final model was evaluated, and the results of the VPC are displayed in 
figure 11, as the prediction of the median concentration (solid line), and the 
95% CIs (grey area). The VPC results confirmed the adequacy of the model 
predictions in describing the observed data. 
 
 
 
Figure 11. Visual predictive check (95% prediction interval) of the 
pharmacokinetic model. Observed data is depicted as circles. The solid and 
dashed lines are the median of the predicted and observed data, respectively. 
The grey shaded areas are the 95 confidence interval of the simulated 
median, 2.5
th
 and 97.5
th
 percentile, respectively. From Paper IV. 
 
 
 
 
Optimization of HIV therapy in patients co-infected with tuberculosis 
 
55 
 
 
Figure 12. Observed EFV plasma concentrations over a 6-week follow up in 71 
patients on concomitant HIV and TB treatment. Generally, the figure shows 
lower concentrations in patients who have been on HAART since several months 
before initiation of TB treatment (represented by dashed red lines) compared to 
naive patients who initiated HAART after some weeks of TB treatment 
(represented by solid green lines). From Paper IV. 
 
 
 
Figure 13. Goodness of fit plots for the final pharmacokinetic model for 
efavirenz. The fine solid lines are the line of identity or the zero reference lines. 
The heavy solid red lines represent the tendency curve. From Paper IV. 
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In patients pre-treated for TB (Group A), it appears that the CL/F of EFV was 
under the influence of enzyme induction which was elicited by the previous 
TB treatment before the initiation of EFV-based HAART. While in patients 
with previous exposure to EFV-based HAART (Group B), the estimated 
CL/F of EFV was auto-induced by EFV itself. On one hand, rifampicin, one 
of the TB drugs has been shown to induce EFV metabolizing enzymes such 
as CYP2B6 19, 75, 149-151 and CYP3A4 38, 39. Enzymes metabolizing 
EFV were reported to be induced to a maximum degree during the early stage 
of RBT (first eight weeks after RBT administration), indicating no prolonged 
enzyme induction to affect EFV kinetics over time 12. This suggests that 
rifampicin enzyme induction was still ongoing the day of initiation of EFV-
based HAART in group A patients who had less than eight weeks of TB 
treatment, which was the case for 85% of the patients of this group. This 
indicates that enzyme induction had not yet reached its maximum, explaining 
the lower CL/F of EFV at baseline for patients of this group compared to 
group B patients. On the other hand when treating HIV alone, EFV was 
reported to accelerate its own metabolism by inducing CYP2B6 and CYP3A4 
up to a prolonged period of 3 months to reach almost its maximum 13, 14. 
This indicates that in group B, EFV auto-induction was still ongoing for 
patients who have been treated with HAART for a period of less than 3 
months, whereas it has reached its maximum for those who have been treated 
with HAART for a period of more than 3 months. Since patients of this group 
may have been under HIV treatment for several months, EFV metabolizing 
enzymes were highly induced up to the maximum in patients of this groups, 
which could explain the higher efavirenz CL/F values observed at baseline 
for group B compared to group A patients.  
 
Furthermore, when treating both HIV and TB, Ngaimisi et al. (2011) 12 
reported an early induction of EFV metabolizing enzymes by RBT and a non-
significant additive or synergistic effects for EFV auto-induction over and 
above ongoing RBT. The present data however, showing an increase of 51% 
and 55% of the CL/F in group A and B patients, respectively, argue for a 
significant contribution of EFV auto-induction to the overall induction. This 
indicates that the increase of the CL/F observed was dependant on the 
inducing effects of both RBT and EFV. 
 
An influence of CYP2B6 genetic polymorphism on the CL/F of EFV was 
observed, according to which carriers of G/G genotype had higher CL/F 
compared to carriers of G/T and T/T genotypes. This is comparable to the 
significantly higher EFV trough concentrations and exposure in T/T than in 
G/T and G/G genotype patients reported by Ramachandran et al. (2009) 75  
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in Indians, and the longest half-life for T/T genotype individuals reported by 
To et al. (2009) 152 in Chinese; all these implying a lower and higher CL/F 
of EFV for T/T and G/G genotype patients, respectively. Similar trends were 
also reported in African populations, such as South Africans 77, Ghanaians 
74 and Zimbabwean patients 87. Our results imply that genetic 
polymorphism in CYP2B6 516G>T should be taken into account when 
adjusting EFV dose and patients under EFV-based treatment monitored 
closely since carriers of T/T and G/G genotypes may be at risk of supra-
therapeutic levels (responsible for CNS side effects) and sub-therapeutic 
levels of EFV (responsible for treatment failure), respectively. Overall, 
estimated CL/F values for EFV were in agreement with those previously 
reported 16, 17, 87. 
 
Paper IV aimed to estimate the CL/F of EFV by accounting simultaneously 
for CYP2B6 genetic polymorphisms and for DDIs caused by enzyme 
induction. Reported CL/F values of EFV differed according to the treatment 
nature (whether the patients were under TB treatment before initiation of 
EFV-based HAART or whether they had previous exposure to HAART 
before being diagnosed for TB and initiation of its treatment). CL/F values 
were also different according to the CYP2B6 516G>T genotype carried by 
the patients (G/G, G/T and T/T for extensive, intermediate and poor 
metabolizers, respectively). The present results indicated higher CL/F values 
in patients with previous exposure to HAART and in carriers of 
CYP2B6 516G/G genotype in the two patient groups, and similarly lower 
CL/F values were observed in carriers of CYP2B6 516T/T genotype in the 
two patient groups. Overall, this indicates that previous exposure to HAART 
increased the CL/F, regardless of CYP2B6 516G>T polymorphisms, and 
CYP2B6 516G>T polymorphisms determined the CL/F regardless of the 
previous treatment received by the patients. This suggests that the CL/F of 
EFV in the population studied was variable due to whether the patients were 
previously mono-treated for TB or HIV and to CYP2B6 genetic 
polymorphisms, implying that both CYP2B6 genetic polymorphisms and the 
current treatment nature should be taken into account when adjusting EFV 
dose, with caution in patients who have been treated with HAART since 
several months. 
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Taken together, the data from this thesis demonstrated that CYP2B6 
polymorphism is the main pharmacogenetic determinant of EFV exposure in 
the patient population studied, being associated with higher EFV plasma 
levels and predicting 72% of the variability in EFV plasma levels. In addition 
to CYP2B6, CYP enzymes of the accessory metabolic pathways of EFV 
(CYP1A2 and CYP2A6) were shown to explain variability in EFV plasma 
levels. During the management of HIV/TB co-infection, both HIV and TB 
therapies are involved in drug-drug interactions, with TB therapy 
significantly decreasing EFV plasma levels and long term HAART 
increasing the clearance of EFV. Even though it is clear from this thesis that 
specific CYP genotypes and TB co-treatment do have a definite effect on 
EFV plasma levels  causing its variation, this however does not seem to 
influence the efficacy of the EFV-based regimens in general. 
 
The specific findings were:  
 
 In comparison to several other published methods for the 
quantification of EFV, the developed HPLC method presents the 
advantage of being simultaneously rapid, highly selective, and 
straightforward, making it suitable not only for PK studies, but also 
for therapeutic drug monitoring in patients with HIV/AIDS alone or 
co-infected with TB at sites with less resourced settings. 
 
 Investigated allele and genotype frequencies showed genetic 
variation in almost all SNPs studied, indicating a need for further 
genomic and genotype-phenotype investigations to explore the 
clinical influence of polymorphisms in the cytochrome P450 and its 
relevance in the population studied. 
 
 A difference between CYP1A2 -739T/G and T/T genotypes was 
observed only in the presence of RBT, suggesting that this SNP may 
be of interest in slow CYP2B6 metabolizers. 
 
 CYP2B6 516T/T genotype was found to be associated with higher 
EFV plasma levels, which could pre-dispose carriers of this genotype 
to CNS toxicity. 
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 CYP2A6 1093G>A and CYP2B6 983T>C were identified as 
additional independent predictors of EFV levels beyond that 
provided by CYP2B6 516G>T polymorphism, indicating that 
genotypic data for these SNPs should be taken into consideration 
when estimating the appropriate dose of EFV for the management of 
HIV/AIDS. 
  
 A high PPV for CYP2B6 SNPs was observed in predicting supra-
therapeutic EFV plasma levels, indicating the validity of predictive 
genotyping in CYP2B6 SNPs to identify patients who could be at 
risk of EFV-related CNS toxicity and need adjusted EFV dose. 
 
 Rifampicin-based TB therapy was shown to significantly lower EFV 
plasma levels but not HIV-treatment response, suggesting that taking 
into account TB treatment effects during dose adjustment for EFV 
could be made rather at individual level. Specifically, the impact of 
Rifampicin-based TB therapy on EFV plasma levels could be 
assessed in patients suspected being at risk of sub-therapeutic levels 
and dictate dose adjustment only when the clinical response is 
affected. 
 
 Long term exposure to HAART was found to increase the clearance 
of EFV, indicating that not only should the patient genotype status 
with respect to CYP2B6 be taken into account, but also each 
individual patient treatment history, with caution to previous 
exposure to HAART. 
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